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Abstract 
(A) Solid phase synthesis of oligonucleotides are well documented and are extensively 
studied as the demands continue to rise with the development of antisense, anti-gene, RNA 
interference, and aptamers. Although synthesis of RNA sequences faces many challenges, most 
notably the choice of the 2' -hydroxy protecting group, modified 2' -O-Cpep protected 
ribonucleotides were synthesized as alternitive building blocks. Altering phosphitylation 
procedures to incorporate 3' -N,N-diethyl phosphoramidites enhanced the overall reactivity, thus, 
increased the coupling efficiency without loss of integrety. Furthermore, technical optimizations 
of solid phase synthesis cycles were carried out to allow for successful synthesis of a homo UIO 
sequences with a stepwise coupling efficiency reaching 99% and a final yield of 91 %. 
(B) Over the past few decades, dipyrrometheneboron difluoride (BODIPY) has gained 
recognition as one of the most versatile fluorophores. Currently, BODIPY labeling of 
oligonucleotides are carried out post-synthetically and to date, there lacks a method that allows 
for direct incorporation of BODIPY into oligonucleotides during solid phase synthesis. 
Therefore, synthesis of BODIPY derived phosphoramidites will provide an alternative method in 
obtaining fluorescently labelled oligonucleotides. A method for the synthesis and incorporation 
of the BODIPY analogues into oligonucleotides by phosphoramidite chemistry-based solid phase 
DNA synthesis is reported here. Using this approach, BODIPY-labeled TlO homopolymer and 
ISIS 5132 were successfully synthesized. 
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Chapter 1- Nucleic Acid Synthesis 
1.1 Introduction to Nucleic Acids 
The study of deoxyribonucleic acids (DNA) can be dated back to the 1850s beginning 
with the discovery of a hereditary material through breeding experiments of garden peas. l This 
hereditary material was first isolated by Friedrich Miescher in 1869 as his work began with the 
study of proteins in leucocytes, however, his investigations led to the discovery of an enigmatic 
material whose properties were significantly different from proteins.2 Since the isolation of this 
material was from the nucleus of cells, he named the substance "nuclein". Although isolation of 
nuclein was successful, this substance was contaminated with various proteins and thus was 
considered as a nucleoprotein. The first protein-free material was obtained by Richard Altmann 
in 1889 to which he exchanged the term "nuclein" to "nucleic acids". Fundamental discoveries 
such as the landmark paper by Oswald Avery, Colin Macleod, and Macyln McCarty in 1944 
suggested that DNA was the true carrier of genetic information and not proteins.3 This proposal 
was confirmed by Alfred Hershey and Martha Chase in 1952 using radioactive phosphorus-32 to 
label the DNA of T2 bacteriophages.4 It was not until X-ray diffraction images gathered by 
Rosalind Franklin and Morris Wilkins5 in 1953 that enabled James Watson and Francis Crick, in 
the same year to propose the current widely accepted DNA double helix mode1.6 
Nucleic acids are macromolecules that are structurally composed of a nitrogenous 
heterocyclic base, a pentose sugar, and a phosphate residue. Nucleic acids exist in one of two 
forms: ribonucleic acids (RNA) or deoxyribonucleic acids (DNA). Distinguishable differences 
among these two forms can be found in their core frame as RNA possessing a fJ-D-
ribofuranoside sugar and DNA containing a fJ-D-deoxyribofuranoside sugar. Furthermore, the 
14 
nitrogenous bases found in DNA and RNA differ due to the replacement of thymine in DNA 
with uracil in RNA. However, cytosine, guanine, and adenine remain the same in both nucleic 
acid forms as the principle building block (Figure 1-1). 
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Figure 1-1 Structural comparison between RNA (left) and DNA (right); (Courtesy: National Human 
Genome Research Institute). 
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"_ 1.2 Approaches for Internucleotide Condensation 
Publication of the landmark paper describing the structure of DNA's double helix by 
Watson and Crick in 19536 revealed more than the simple elucidation of its assembly and 
arrangement. From a chemist's point of view, it revealed the chemical ingenuity of genetic 
information and the genotypic and phenotypic result of these biological molecules. Naturally, it 
was not long before chemists attempted to synthesize these biomolecules. Even with the 
chemical structure of DNA established, analytical techniques in the 1950's were rather limited. 
However, the birth of molecular biology, and the demand for more advanced tools to study 
proteins and nucleic acids sparked a new era of biotechnology to allow precise and accurate 
analysis of such delicate biomolecules. Particularly with the advent of solid phase peptide 
synthesis,7 this concept was applied to nucleic acids and has since revolutionized synthetic 
nucleic acid chemistry. 
General syntheses of nucleic acids are often described as limited due to their sensitivity 
towards a wide range of chemical reactions. Acidic and basic environments often lead to the 
migration andlor hydrolysis of the phosphodiester backbone in RNA, and the nitrogenous 
heterocyclic bases in both DNA and RNA are susceptible to oxidation/reduction and alkylation. 
Furthermore, nucleic acids are decorated with various functionalities that often complicate 
chemical reactions if not accounted for. Therefore, every chemical approach towards the 
condensation of the 3' - to 5' - intemucleotide linkage must take into account not only the 
protection of various functionalities within the nucleotide but also the deprotection processes to 
allow for high yields and purity. 
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1.2.1 Michelson and Todd Dimer Experiment 
The first chemically synthesized oligonucleotide was accomplished by Michelson and 
Todd in 1955. The final product was a thymidine dimer that contained one phosphate linkage and 
was an active substrate for enzymatic digestion.8 The research group began with a 5' -O-acetyl 
thymidine 1 and treated it with the crude material prepared from diphenyl chlorophosphate and 
ammonium monobenzyl phosphite in benzene. Further additions with N-chlorosuccinimide 
yielded 5' -O-acetyl thymidine 3' -benzyl phosphochloridate 2. This activated phosphochloridate 
was coupled with the 3' -O-acetyl thymidine 3 to yield the phosphotriester 4 that was then 
deprotected to the final dithymidine product 5 (Scheme 1-1). Being the first documented 
methodology in oligonucleotide synthesis, there were disadvantages such as the inability to 
synthesize anything larger than a dimer and the slow coupling reactions. Furthermore, the 
unstable intermediate, benzyl phosphochloridate 2, often led to hydrolysis and debenzylation.9 
Nevertheless, this paper proved that chemical synthesis of oligonucleotides was possible. 
o 
o "(;: 
'CNH AcO N 0 N~O . .. ~ 'Co AcO I,ll + ~ -- I NH 0:-r"-o Bn ..... 'CI HO N~O 
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Scheme 1-1 Reagents and conditions: i) NH/(PhCH2)HP03- , (PhO)2P(O)Cl, 2,6-1utidine, benzene; ii) N-
chlorosuccinimide, CH3CN , benzene; iii) 2,6-1utidine, CH3CN; iv) H2S04, EtOH, H20; v) Ba(OH)2, H20. 
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1.2.2 Khorana and the Phosphodiester Approach 
In the late 1950's, Har Gobind Khorana entered the field of oligonucleotide synthesis in 
which he proposed the phosphodiester approach that soon became the dominant method in 
oligonucleotide synthesis for the next 15 years.lO In the early 1960' s, he had made two 
extraordinary contributions to this field, one of which has yet to be modified and is used almost 
exclusively in modem day synthesis of oligonucleotides. His first contribution was the 
development of the phosphodiester approach that allowed for synthesis of oligonucleotides of 
more than a few bases 10ng.11 -13 Starting from the 5' -O-trity1thymidine 6 and 3' -O-acety1 
thymidine 5' -phosphate 7, the two building blocks were coupled with the addition of N,N'-
dicyclohexylcarbodiimide (DCC) and to1uene-4-su1fony1 chloride (TsC1). Subsequent 
deprotection of the trity1 and acetyl groups yielded the final d(TpT) dimer 9 (Scheme 1-2). 
o 
"CJ: Tr0'd +0 0 
OH 0 ~NH 
II l .. A 
6 HO-P-O N 0 old 
i, ii 
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OAe 
7 8 9 
Scheme 1-2 Reagents and conditions: i) TsCl, CsHsN; ii) DCC, CsHsN; iii) AcOH-H20 (4:1 v/v); iv) aq. 
Some drawbacks with this methodology were that the intemucleotide linkages were not 
protected and were left as negatively charged, thus, leading to undesired side-reactions, such as 
pyrophosphate branching by-products and greater difficulty in purification. Furthermore, 
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· _ coupling yields of approximately 50-70% for each coupling reactions drastically reduced the 
overall yield of an oligonucleotide. To increase the yield, other choices of activators such as the 
use of mesitylene-14 10 and 2,4,6-triisopropylbenzene-sulfonyl chioridesI5 11 were used in place 
of Dee as the coupling reagent. Nevertheless, the cumulative low yields and side reactions 
consequently made purification of the final product difficult and very labor intensive as the 
products must be purified after every step. The most successful outcome of this project led to the 
total synthesis of an active 72-mer tyrosine tRNAI6 and yeast alanine tRNAI7 by joining 
chemically synthesized oligonucleotide fragments enzymatically. This methodology was later 
replaced by the phosphotriester approach. 
The second major contribution by Khorana was the use of various protecting groups both 
at the 5' -OH of nucleotides and on different base residues. IS The key to success in developing an 
efficient and effective approach in oligonucleotide synthesis is the ability to selectively remove a 
specific protecting group at any desired time. This was no simple task as these protecting groups 
must be achiral, inexpensive, soluble in organic solvents, compatible with conditions for chain 
assembly, and must be efficiently added and removed.9 The trityl family of protecting groups 
developed by Khorana satisfied many of these conditions; most notably the dimethoxytrityl 
(DMTr).ls The acid-labile trityl protecting groups are advantageous due to their ability to 
efficiently stabilize the carbocation formed during deprotection. Furthermore, each member of 
this family will produce a distinct color when ionized, making it an effective means for 
quantitative and qualitative analysis (Figure 1-2). The second set of protecting groups were also 
developed to protect the exocyclic amino groups of nuc1eosides; isobutyryl for gaunosine, 
benzoyl for adenosine and cytidine (Figure 1-3). 
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Figure 1-2 Three commonly used 5'-OH protecting groups. 
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Figure 1-3 Exocyclic amino protecting groups for base residues. 19 
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1.2.3 Robert Letsinger: The Phosphotriester and Phosphite triester approach 
Khorana's significant contributions and research inspired many, especially one of his 
own students, Robert Letsinger, who went on to modify and improve on the phosphotriester 
approach.2o Beginning his career at Northwestern University in the late 1940s specializing in 
boron chemistry, Letsinger later entered the field of solid phase peptide synthesis. However, he 
was not the only researcher developing a scheme for the solid phase synthesis of peptides; 
Robert Bruce Merrifield was able to publish this work first and eventually won the Nobel Prize 
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· _ in 1984.7 Letsinger then applied the solid phase approach to the synthesis of oligonucleotides 
using the phosphotriester approach.21 
The advantage of the phosphotriester approach was the choice to protect the phosphate 
internucleotide bridge to prevent phosphoryl branching and to keep the oligonucleotides neutral 
for easier chromatographic purification. The use of the benzyl protecting group in the Michelson 
and Todd experiment was unfavorable due to its instability in pyridine, thus the search for 
alternative protecting groups that were stable yet labile enough for efficient removal were in 
demand. In the late 1960s, three independent research groups applied the phosphotriester 
approach with different intemucleotide protecting groups. Letsinger and Ogilvie used the 2-
cyanoethyl protecting group20 12, Eckstein and Rizk used the 2,2,2-trichloroethyl group22,23 13 
and Reese and Saffhill with the use ofa phenyl group 14 (Figure 1_4).24 
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Figure 1-4 Alternative internucleotide protecting groups. 
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Of the three proposed phosphate protecting groups, the 2-cyanoethyl12 was deprotected 
with aqueous ammonia25, however it was also shown to be too labile in solution phase synthesis 
and loss of this protecting group was readily observed. The 2,2,2-trichloroethyl group 13 was 
also found to be unfavorable as yields after deprotection with zinc dust in 80% acetic acid were 
inadequate.26 Lastly, the use of the phenyl protecting group was initially unsatisfactory due to the 
unselective deprotection processes via alkaline hydrolysis which may lead to oligonucleotide 
cleavage (Scheme 1-3 A). However, this problem was later resolved due to the ease of aryl 
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substitution. It was observed that addition of an electron-withdrawing substituent would increase 
the selectivity of the hydrolysis process thus giving a greater yield of products. One such 
substitution derivative that had shown tremendous improvement was the 2-chlorophenyl group; 
its removal by oximate treatment resulted in no observable intemucleotide hydrolysis (Scheme 1-
3 B).27. This method soon allowed chemists to consistently synthesize oligonucleotides that were 
reproducible for their own purposes and research. 
0 0 0 0 HO- II o-O-~-OR o-O-~-O-A o-O-~-OR .. -0-P-OR1 + _ I 1 + - I _ I 1 I 
OR2 OR2 
0- OR2 
15 16 17 18 
CI ~ 2' 6-0-~-OR ii 0 II B + • ~ ~ .. -0-~-OR1 I 1 - OR2 OR2 H N-O-P-OR N I 1 22 19 I OR2 OH 
20 21 
Scheme 1-3: Reagents and Conditions: (B): i) TMG, dioxane:H20 (1:1 v/v), ii) TMG, CH2Clz. 
Exploration of various intemucleotide protecting groups had inadvertently allowed 
Letsinger in the mid 1970s to establish pioneering work with different phosphorylation 
methodologies. In 1976, Letsinger and Lunsford discovered that the significant reactivities of 
phosphites were much higher than those of phosphates. 28 Thus, the phosphotriester approach was 
modified by taking advantage of the enhanced reactivity of phosphites. This observation was not 
obvious at first, as one would think P(V) centers would be more electrophilic by having an 
enhanced inductive electronegative withdrawing effect on neighboring oxygens. This concept 
22 
.. was only true to some extent as the real driving force for nucleophilic displacement was the 
transition state in which P(IlI) species are formed. Having an oxygen atom double bonded to the 
phosphorous center induces a trigonal bipyrimidal transition state which is more sterically 
hindered compared to a P(IIl) with a tetrahedral molecular geometry, thus P(IlI) centers are more 
favored and are more reactive in this regard. However, this modified procedure required an extra 
step of oxidation from P(IlI) to P(V), as these intermediates were not stable during deprotection 
of the 3' -O-trityl 26 of the elongating nucleotides (Scheme 1-4). Unfortunately, these 
phosphodichloridites 24 are highly susceptible to hydrolysis and need to be handled with great 
care.9 Furthermore, the phosphodichloridite reagents 24 used to activate the 3' -OH are 
bifunctional, thus it may react twice to give a mixture of 3' - to 5' - and 3' - to 3' - intemucleotide 
linkages. Nevertheless, this approach paved the way for the current industry standard for 
oligonucleotide synthesis, the phosphoramidite approach. 
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Scheme 1-4: Reagents and conditions: i) 2,6-lutidine, THF, -78°C; ii) 2,6-lutidine, THF; iii) 12, THF, 
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1.2.4 Caruthers, Beaucage and the Phosphoramidite Approach 
Marvin Caruthers who completed his PhD under Letsinger's supervision, proceeded to 
further his studies as a post-doctoral associate with Khorana at the Massachusetts Institute of 
Technology (MIT). It was not until in 1981 that Caruthers and Beaucage proposed one change to 
the phosphite triester approach that would revolutionize routine synthesis of oligonucleotides. By 
simply replacing one of the chloride substituents with a secondary amine, they were able to 
completely eliminate the bifunctionality in the phosphite approach, yet retain the reactivity.29 An 
activator such as IH-tetrazole, was used to facilitate the coupling between two nucleotides 
(Scheme 1-5). This led to a second advantage where these new building blocks, or the 
phosphoramidites, were synthesized in advance and were stable for storage.9 Being only active in 
the presence of a weak acid, large quantities and commercial sales of these phosphoramidites and 
their respective reagents were made possible. The introduction of this chemistry to solid phase 
synthesis of oligonucleotides gave rise to a new company, Applied Biosystems (ABI). 
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Scheme 1-5: Reagents and conditions: i) THF, (i-Pr)2NEt; 11: CH3CN, 1H-tetrazole; iii) 
24 
By the late 1980s, this method became the industry standard for oligonucleotide synthesis 
and ABI had virtually a monopoly within this market due to the exclusive license to Caruther's 
patents. The solid phase synthesis cycle has remained relatively unchanged for three decades. 
Moreover, solid phase synthesis of DNA has been very well established with minimal coupling 
times and coupling step-wise yields are often greater than 99%. Thus, the impact of nucleoside 
phosphoramidites in oligonucleotide synthesis has been unsurpassed. There have been very few 
recent phosphitylation methodologies that have yet to even rival phosphoramidite chemistry for 
solid phase synthesis. 
1.3 Solid Phase Synthesis of Oligonucleotides 
The proposal for carrying out organic reactions on a solid support was first introduced in 
1963 by Merrifield, however, the chemistries applied were mostly directed towards peptide 
synthesis.7 However, peptides and oligonucleotide synthesis do share some common ground in 
that both require extensive protection, deprotection, purification and chain elongation by addition 
of a building block. Thus, solution phase syntheses are often tedious and very time consuming. 
By moving these chemical reactions on a solid support, the need to purify between each step was 
eliminated due to the addition of a washing step in which excess reagents and other unbound by-
products are removed. Therefore, reagents and stepwise protocols were modified to 
accommodate oligonucleotide synthesis on a solid support. 
With respect to synthesis of oligonucleotides, research and development of solid supports 
are divided into two concepts: the solid support material and the linker that allows for nucleotide 
immobilization. Solid supports such as controlled pore glass (CPG) and macroporous 
polystyrene (MPPS) are the current industrial standard. An initial nucleoside is often anchored 
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covalently to the solid support via succinate linkages. However, the disadvantage with having an 
initial nucleoside already attached to the solid support means that four different types of solid 
supports are required depending on the sequence to be synthesized. Therefore, universal linkers, 
which are solid supports that lack an initial loading of a nucleoside, are becoming increasingly 
popular due to their flexibility. These linkers possess a pseudo 5' -protected bridge to allow initial 
coupling of any desired nucleoside (Figure 1-5). Upon treatment with a base, such as ammonium 
hydroxide, the oligonucleotides would be cleaved from the CPG or universal linkers. 
o 
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Figure 1-5 Examples of general purpose solid support linkers. Preloaded nucleoside CPG (left) and 
Universal Linker (right). 
Currently, automated solid phase synthesizers operate in a very methodical manner where 
cycles of chemical reactions are employed in a specific sequence to allow efficient synthesis of 
the desired oligonucleotide. Each cycle of solid phase synthesis may be broken down into four 
basic chemical steps: detritylation, coupling, capping, and oxidation. This cycle repeats itself 
until the desired sequence of interest is constructed. The initial detritylation step removes the 5'-
DMTr protecting group to reveal the 5' -OH function of the nucleotide by treatment with a 
diluted solution of 3% trichloroacetic acid (TCA) or dichloroacetic acid (DCA). After extensive 
washing, the solid supports are exposed to the next nucleotide phosphoramidite to allow for 
coupling in the presence of an activator such as 1H-tetrazole. At this stage, there will always be a 
small percentage of unreacted nucleotides due to failed coupling and thus needs to be accounted 
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for by capping the 5' -OR with acetic anhydride. If this step is omitted then the truncated 
sequences would be allowed to further couple in the following cycles, thus, generating many 
different by-products. Lastly, the highly unstable phosphite triester backbone is oxidized to its 
respective phosphate triester. These four chemical steps are then repeated until the desired 
sequence is assembled (Figure 1-6). Subsequent treatment with aqueous ammonia at 550 C 
overnight will cleave the oligonucleotide from the solid support, hydrolyze acyl protecting 
groups present on the nucleobases, and removal of the ~-cyanoethyl protecting groups. 
Detritylation 
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1 Oxidation 
Capping 
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Figure 1-6 The required four chemical steps for oligonucleotide extension. 
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1.4 Challenges in the Chemical Synthesis of RNA 
Methods for synthesizing DNA sequences are well established and are common practice 
In both the industry and many academic research laboratories. However, synthesis of 
oligoribonucleotides is still faced with many challenges due to the presence of an extra 2' -OH. It 
has already been demonstrated that each DNA building block contains multiple protecting 
groups (two to three depending on the nucleoside); consequently, the addition of one more 
protecting group tremendously complicates the overall chemistry. The need to use multiple 
protecting groups on one molecule demands that each group must be compatible to one another 
such that individually, the chemistries involved in their deprotection must not disturb other 
protecting groups. Therefore, each protecting group must be unique enough to allow for highly 
selective protection and deprotection. 
The most fundamental criteria in the chemical synthesis of RNA in both solution and 
solid phase is the choice of the 2' -protecting group. To date, there have been many different 
options, each with its own respective advantages and disadvantages. However, there are three 
general aspects that should be considered: (1) the protecting group must be easily introduced to 
the RNA building block, (2) once introduced, the protecting group should remain intact and 
stable during oligoribonucleotide elongation, and (3) the chemistries involved in its deprotection 
should be under conditions that allow the final RNA product to remain stable.30 
Having a protecting group easily introduced involves not only the ability to produce 
products in high yields but should also include the ease of access to commercially available 
reagents. The success in oligoribonucleotide synthesis should not involve extremely expensive or 
highly elaborate chemistries otherwise attention towards its uses may be overlooked. Secondly, 
the 2' -protecting group must exhibit minimal migration profiles from the 2' - to the 3' -OH and 
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that regioselective addition of the protecting group to the 2' -OH position is highly desirable. If 
this is not the case then extensive purification would be required in order to retrieve the preferred 
product, otherwise phosphorylation will occur at the wrong position leading to 2' 7 5' 
intemucleotide linkages. 
Throughout the duration of the solid phase cycles of oligoribonucleotide synthesis, the 
2' -protecting groups must remain stable and intact especially during the detritylation step to 
remove the 5' -protecting group. Concomitant loss of the 2' -protecting group will result in either 
chain cleavage via acid-catalyzed hydrolysis, undesired chain elongation from the 2' -OH 
position or migration t9 the 3' -OH. Furthermore, it is common to remove all the protecting 
groups on the final oligoribonucleotide product except those on the 2' -OH for storage purposes 
and to protect the material from endonuclease digestion. 
The last criterion is often the most complex and difficult problem to solve due to the 
relative fragile nature of RNA. When the time comes to remove the 2' -protecting group to yield 
the final fully-deprotected RNA molecule, the deprotection conditions must be compatible with 
RNA stability. Whether the 2' -protecting group is an acid-labile or base-labile type, if the 
solution is either too acidic or basic, both environments will most likely lead to intemucleotide 
hydrolysis and/or migration (Figure 1-7). Overall, the 2' -protecting group must exhibit some 
degree of acid-stability due to the detritylation step and also base-stability due to the deprotection 
conditions of both the nucleobase and phosphoryl protecting groups and release from the solid 
support from ammonium hydroxide treatment. 
2' -tert-Butyldimethylsilyl- (TBDMS) and the 2' -1-(2-fluorophenyl)-4-methoxypiperidin-
4-yl- (Fpmp) 3' -(2-cyanoethyl)-N,N-diisopropylphosphoramidites were the first commercially 
available monomeric building blocks containing 2' -protecting groups that satisfied the above 
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mentioned criteria.31 ,32 However, both methods require relatively long coupling time (ca. 10 
min), which could lead to potential side-reactions. It has been proposed that the general steric 
bulk of most 2' -protecting groups hinder the coupling process from its neighboring 3'-
phosphoramidite. 
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Figure 1-7 A: Base-catalyzed hydrolysis of RNA sequences. B: Acid-catalyzed hydrolysis and migration 
of the intemucleotide linkage. 
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1.5 2'-Protecting Groups for Solid Phase Synthesis of RNA 
1.5.1 SHy} Ether Based Protecting Group 
1.5.1.1 tert-Butyldimethylsilyl (TBDMS) 
The TBDMS protecting group is currently the most widely used for protecting 2'-
hydroxy functions of ribonucleosides and is readily available commercially. Even though its 
discovery dates back to the early 1970s and that TBDMS was one of the first protecting groups 
developed for ribonucleosides, it remains as a popular choice in RNA synthesis.33,34 TBDMS 
received its first true success in 1988 in the synthesis of a 77-nucleotide-Iong RNA sequence.35 
TBDMS may be effectively removed by treatment with tetra-n-butylammonium fluoride 
(TBAF). However, even with its significant contributions and tremendous success in both solid 
phase and solution phase synthesis of RNA, TBDMS-based ribonucleoside building blocks 
suffer from several disadvantages. First, incorporation of the TBDMS into riboncleosides lacks 
regioselectivity between 2'- and 3' -hydroxy functions. Therefore, a mixture of regioisomers is 
always obtained. Careful purification and isolation are required when separating the two 
regioisomers since any contamination of the 3'-TBDMS will result in the formation of non-
natural 2'~5' intemucleotide linkages.36 Furthermore, after obtaining the preferred 2'-TBDMS 
ribonucleoside, there is still the possibility of (2' ~ 3') isomerization whereby migration from the 
2' - to the 3' -hydroxy function is observed.37 
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Other limitations such as TBDMS' inability to remain stable during deprotection of N-
acyl nucleobase protecting groups, thus, undesirable loss of 2' -TBDMS would be observed. 
However, this loss may be suppressed by using more base-labile nucleobase protecting groups.38 
Lastly, the coupling time associated with 2'-TBDMS protected phosphoramidites are long, often 
requiring 10 min of coupling time in order to achieve 98% step-wise yield.30 This may be 
attributed to the steric hindrances of the 2'-TBDMS group, thus great strides have been made to 
reduce the overall steric bulk of the phosphoramiditebuilding block. Replacement of N,N-
diisopropyl phosphoramidites with the less hindered N,N-diethyl or N,N-methylethyl 
phosphoramidites were synthesized and a reduction of coupling time to seven min was 
obtained.39, 40 
1.5.2 Ester Based Protecting Groups 
1.5.2.1 Levulinyl (Lev) group 
The levulinyl group has been previously used to protect the 5' -hydroxy function for the 
synthesis of oligoribonucleotides.41 Recently, this group was proposed to protect the 2' -hydroxy 
function since compatibility with the acid-labile DMTr group at the 5' -position has been 
demonstrated (Figure 1_8).42,43 The 2'-O-Lev group may be efficiently cleaved via 
hydrazinolysis. There are however, several drawbacks with the Lev group in both synthesis and 
compatibility with the nucleobase and intemucleotide protecting groups. First, synthesis of 2'-
Lev protected ribonucleosides is not regioselective, that is, addition occurs at both the 2' - and 3' -
hydroxyl functions and subsequent phosphitylation yields of 2' -protected ribonucleosides range 
between 7%-29%. Furthermore, separation and isolation of the desired product are often 
challenging and sometimes impossible to obtain a regioisomerically pure product. Second, given 
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that the Lev is a base-labile protecting group, concurrent deprotection of both the internucleotide 
and nucleobase protecting groups will result in loss of the Lev group as well, therefore, isolation 
of 2' -protected RNA sequences is not possible. Last, an overall coupling step-wise yield of 
approximately 98% was observed with the use of 5-ethylthio-1H-tetrazole as activator; however, 
the coupling time has to be increased to 14 minutes. 
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Figure 1-8 2' -levulinyl protected ribonucleoside. 
1.5.3 Protected protecting groups 
The protected protecting group strategy was first described by Chattopadhyaya and 
subsequent investegation of newer acetal protecting groups for the 2' -hydroxy functions of RNA 
were reported by Pfleiderer.44-46 There are a few advantages with using a two tier protection 
system for the 2' -hydroxy function of ribonucleosides. First, the initial extension of the acetal 
alleviates steric tension between the 2' -protecting group and the 3' -phosphoramidite, which has 
been known to affect coupling efficiency. Second, this highly labile acidic acetal is further 
protected to reduce its lability such that it remains intact during solid phase synthesis. However, 
general disadvantages are that these systems often require a two-step deprotection process for the 
complete removal of the protecting group. 
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1.5.3.1 Acetallevulinyl ester (ALE) 
To improve on the original levulinyl group for 2' -hydroxyl protection, development of 
the acetal levulinyl ester permits easier separation of the 2' - from 3' -protected ribonucleoside 
phosphoramidites (Scheme 1_7).47 Furthermore, the use of the ALE system allows for 
regiospecific addition to the 2' -hydroxy function with good yields of 87%. With the use of 4,5-
dicyanoimidazole as the activator, step-wise coupling yields of greater than 98% with a coupling 
time of I min were demonstrated. The obvious superiority of the ALE system over the Lev 
protecting group displayed potential attractiveness of the ALE in the synthesis of longer 
oligoribonucleotide sequences. 
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Scheme 1-7: Reagents and conditions: i) H2NNH2,H20 (0.5 M), C5H5N-AcOH (3:2 v/v). 
1.5.3.2 (2-Nitrobenzyloxy) methyl (2-NBOM) and (4-nitrobenzyloxy) methyl (4-NBOM) 
The development of both 2-NBOM48 and 4-NBOM49 were based on advancements of the 
original 2-nitrobenzyl protecting group. 50, 51 These nitrobenzyl derivatives were unique 2'-
protecting groups since their removal was achieved by photolysis. However, similar to the 
TBDMS protecting group, the incorporation of2-NBOM and 4-NBOMs were not regioselective, 
thus the overall yields often range between 20 to 40%. Despite the low yields, both the 2-NBOM 
and 4-NBOM have been reported to give step-wise coupling yields of greater than 98% with two 
to three minute coupling time. This may be attributed to their flexibility at the 2' -position. 
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· _ However, the photostability of the 2-NBOM were problematic as loss of these protecting groups 
was observed in routine overhead lighting. Complete removal of the 2-NBOM group may be 
effected under photolytic conditions at pH 4. An alternative approach was designed for the 
removal of the 4-NBOM by first reducing the 4-nitro group to its respective amino function. This 
step enhances the cleavage of the 2' -acetal via elimination of imino quinone methide and 
subsequent loss of formaldehyde. 
Figure 1-9 2'-(2-nitrobenzyloxy)methyl (Left) and (4-nitrobenzyloxy)methyl (right) protected 
ribonucleoside. 
1.5.3.3. [(Triisopropy1si1y1)oxy]methyl (TOM) 
It has been demonstrated that the steric bulk of the 2' -protecting groups contributes 
significantly to the overall coupling efficiency. Similar to the 2-NBOM and 4-NBOM, the 
natural flexibility of formaldehyde acetal linkers may be exploited to decrease step-wise 
coupling times. The [(triisopropy1si1y1)oxy]methy1 (TOM) group52 is clearly related to the 
TBDMS group, however with the necessary modifications to enhance coupling efficiency. 
Moreover, the TOM group has a distinct advantage over the TBDMS in that no migration from 
the 2' - to the 3' -hydroxyl function is observed even under strong basic conditions. Nevertheless, 
the TOM group does share TBDMS' regiose1ectivity problem during its introduction to 
nucleosides, giving the desired 2' -TOM protected products in relatively low yields ranging from 
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40 to 60%. When using the 2'-TOM protected phosphoramidite building blocks, coupling times 
have been reduced to three minutes with coupling yields of greater than 99%. Similar to other 
protected protecting groups, a two step deprotection process is required for the removal of the 
TOM group. An initial deprotection of the triisopropylsilyl function is carried out through 
treatment with TBAF (1 M) in DMSO. This is followed by and subsequent loss of formaldehyde 
at 30°C for 14 hrs. 
Figure 1-10 2' -[(triisopropylsilyl)oxy ] methyl protected ribonucleoside. 
1.5.3.4. Bis-(2-acetoxyethoxy)methyl (ACE) 
The first use of2'-ACE protecting group was in the late 1990s developed by the Scaringe 
and co-workers.53, 54 By taking advantage of the extended 2' -formaldehyde acetal to increase the 
overall coupling efficiency, the ACE protecting group is unique in that it does not rely on the use 
of the 5' -DMTr protecting group. Instead, the 5' -hydroxy function is protected with a silyl ether, 
benzhydroxy-bis(trimethylsilyloxy)silyl group. Some advantages with the 2' -ACE group is the 
ability to be regioselectively added at the 2' -OR function and the lack of migration to the 3' -OR 
function. Furthermore, yields of phosphitylation to obtain the phosphoramidite building blocks 
may reach up to 95%. Using these phosphoramidites, average coupling stepwise yields were 
99% with a coupling time of approximately 90 sec. Removal of the ACE protecting group also 
proceeds in a two step reaction by first de acetylation via ester hydrolysis under basic conditions 
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using 40% aqueous MeNH2 to obtain the 2' -O-bis(2-hydroxyethoxy)methyl orthoester. The 2'-
O-bis(2-hydroxyethoxy)methyl orthoester is 10 times more acid labile than the original 2'-ACE 
protecting group itself, thus, a second treatment with tetramethylethylenediamine (TEMED)-
acetate buffer (0.1 M, pH 3.8) at 60°C for 30 min gives the fully deprotected product. One 
disadvantage with the use of the 2' -ACE protected building blocks is their incompatibility with 
conventional solid phase synthesizers. In order for this method to be transferred to solid phase 
synthesis, extensive changes to the synthetic cycles and reagents are required to accommodate 
the changes in chemistry. 
Figure 1-11 2'-Bis-(2-acetoxyethoxy)methyl protected ribonucleoside. 
All of the protected protecting groups described above are well studied and unique for the 
protection of the 2' -hydroxy function. However, there have been a few recent developments in 
both the generation of novel protecting systems and improvements on older protecting groups. 
Table 1-1 Alternative 2' -protected protecting groups for ribonucleosides. 
[4-
(methyl amino )benzyloxy] 
methyl (4_MABOM)55,56 
DMTrol ___ O~ ~ I CI ~ ~N0c, 
OH O'-.,./O~ 0 
TEMED-Acetate buffer 
(0.1 M, pH 3.8), 90oe, 30 
mIn. 
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(2-cyanoethoxy)methyl 
(CEM)59,60 
2-tert-butyldithiomethyl 
(DTMt3 
1.5.4 Acetal based protecting groups 
TBAF in DMSO (0.5lvf) 
with 5% nitromethane, r.t., 
5 h. 
Tris-(2-
carboxyethyl)phosphine 
(pH 7.6), 55°C, 90 min. 
Acetal based protecting groups have gained significant attention due to several 
advantages that would presumably alleviate some shortcomings of the ether derived protecting 
groups. One noticeable advantage is that the incorporation of these acetal based protecting 
groups is regioselective, therefore allowing for high yielding preparation of the desired product. 
Moreover, there has been no evidence to suggest any type of migration from the 2' - to the 3'-
hydroxyl. Last, these protecting groups are completely stable under basic conditions that are 
needed to remove the N-acyl nucleobase protecting groups and to cleave the oligoribonucleotide 
from the solid support. Therefore, such properties have sparked a significant amount of 
enthusiasm for the design and synthesis of various acetal protecting groups. One of the first few 
acetal based protecting groups that were used for oligoribonucleotide synthesis were the 
tetrahydropyran-2-yl (Thp t 6-68 and the 4-methoxytetrahydropyran (Mthp) group.69, 70 However, 
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one distinct disadvantage with the acetal protecting systems is their intrinsic acid-labile nature, 
thus, during the detritylation step of solid phase synthesis, concomitant loss of either Thp or 
Mthp was observed. Such losses often lead to acid-catalyzed hydrolysis of the internucleotide 
linkages. Furthermore, the Thp protecting · group was chiral, therefore resulting in 
diastereoisomeric mixtures that require tedious purification methods for isolation. 
DMTr0'd 
OH 00 
DMTr0'd 
OH 06 
Thp Mthp 
Figure 1-12 First generation of acetal protecting groups. Tetrahydropyran-2-yl (left) and the 4-
methoxytetrahydropyran (right) group. 
1.5.4. l-Aryl-4-alkoxypiperidin-4-yl groups 
Alternative designs of acetal based protecting systems were needed to allow 
compatibility between the 5' -D MTr protecting group and the 2' -acetal based protecting group. It 
was discovered that the rate of acid-catalyzed hydrolysis of ketal systems heavily relied on the 
inductive effects of atom X (Figure 1_13).70,71 It was deduced that if the tertiary amino-ketal 
system possessed an approximate pKa of 2, then under detrity lation conditions, i. e treatment with 
trichloroacetic acid (pKa = 0.66), then the system would be predominately protonated. 
Conversely, during the final deprotecting step where the system is exposed to acidic conditions 
with pH approximately 3.75, then the protecting group would be largely unprotonated. 
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Therefore, the design of the new acetal based systems should behave in such a manner that its 
respective rate of hydrolysis should be virtually independent of a pH range that is slightly above 
and below its pKa. 
Figure 1-13 Inductive effects of piperidinium acetal system as potentially new 2' -protecting groups. 
The first generation of such ketal protecting system was the 1-(2-chloro-4-methyl-
phenyl)-4-methoxypiperidin-4-yl (Ctmp) as it exhibited the characteristics mentioned above.72-74 
The rate of hydrolysis of Ctmp was virtually independent of pH in the range of 0.5 to 2.5. 
Moreover, it was observed that it underwent hydrolysis approximately 40 times more slowly at 
pH 1.0 and approximately 1.5 times faster at pH 3.0 compared to the Mthp group.72 The success 
of Ctmp was short-lived and became overshadowed with the development of the 1-(2-
fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp) group. The Fpmp protecting group possessed a 
very similar hydrolysis profile compared to the Ctmp, however, easy access to readily available 
reagents commercially was favored, thus preference was given to the Fpmp group. In addition, 
the Fpmp enol ether precursor was easily synthesized in high yields and in large quantities 
(Scheme 1_8).75-77 
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Ctmp Fpmp Cpep DMTrOQ DMTrOQ DMTrOQ 
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40 41 42 43 
Scheme 1-8: Reagents and Conditions: i) (a) TsOH-H20 reflux, (b) (MeO)3CH, reflux; ii) Et20-BF3, 0-
The latest development within the l-aryl-4-alkoxypiperidin-4-yl system is the 1-(4-
chlorophenyl)-4-ethoxypiperidin-4-yl (Cpep). Cpep was found to be even more stable under 
acidic conditions (pH 0.5) than Ctmp or Fpmp and more acid-labile at pH 3.75.78 Relative to 
Fpmp, Cpep was l.3 times more stable at pH 0.5 and 2.2 times more acid-labile at pH 3.75, thus 
allowing for greater stability during detritylation yet milder conditions for its removal. The rate 
of hydrolysis of general acetal systems are regarded as "linear," that is, as acidity increases, the 
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relative rate of hydrolysis would increase as well. However, as can be seen from Figure 1-14, the 
rate of hydrolysis ofCpep is virtually independent of pH in the range of 0.5 and 2.5. 
300 
2 0'0 
100 
~ Fpmp 
• • • 0' 
/6 
., !:; 
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pH 
Figure 1-14 Hydrolysis half-life ofCpep and Fprnp at 300 C.78 
1.6 General perspectives and objectives 
The increase in demand for oligonucleotide synthesis has risen over the past decade with 
the development of antisense, anti-gene, RNA interference, aptamers and other medicinal uses 
for oligonucleotides. Thus, the underlying goal to synthesize larger quantities of 
oligoribonucleotides drives research to improve on the chemistry to allow a reduced coupling 
time and greater overall yields. Nevertheless, solid phase synthesis of oligodeoxyribonuc1eotides 
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are well established with step-wise coupling yields greater than 99%, however, there are still 
many gaps and shortcomings in the synthesis of oligoribonucleotides. 
During the synthesis of oligoribonucleotides using a DNA synthesizer, the overall 
synthesis time of a 1.0 /-Lmole scale reaction of a U20 is approximately 5 hours and 45 minutes. 
Each individual coupling step requires 10 minutes of incubation in the presence of an activator 
and the nucleotide building block to achieve approximately 98% coupling yields. The goal of 
this project was to establish the use of 2' -Cpep protected phosphoramidite building blocks as a 
viable chemistry for the solid phase synthesis of RNA. Various phosphitylation procedures and 
technical optimizations were explored to minimize the coupling time and increase the coupling 
efficiency in hopes of reducing the overall synthesis time and improving the quality of the final 
RNA sequence. 
43 
Chapter 2 - Fluorescent Labeling of Oligonucleotides 
2.1 Introduction to Borondipyrromethene Difluoride (BODIPY) 
Over the past few decades, the increasing use of fluorescent methods as research tools 
demonstrates the potential versatility and ability of fluorophores to be applied in many 
disciplines. Its popularity heavily relies on its high fluorescence sensitivity and detection that 
may be used as an alternative to radioactive e1ements.79 Although there are many different 
classes and types of fluorophores, individually, each has its own advantages and disadvantages. 
Some common and well known families of fluorophores such as xanthenes (fluorescein, 
rhodamine, Oregon green, and Texas red), cyanins, and coumarins are often derivatized to label 
various non-fluorescent molecules. However, fluorescent lifetime, quantum yields, and stability 
are conceivably the most important attributes when describing the quality of the fluorophore. The 
quantum yields and fluorescent half-life times are critical in determining the fluorophores' 
detection sensitivity and potential uses. With respect to labeling biomolecules, one would prefer 
high quantum yields, that is, a brighter emission. One such fluorescent molecule is BODIPY. 
Borondipyrromethene difluoride (BODIPY) was first discovered in 1968 by Alfred 
Treibs and Franz-Heinrich Kruezer.80 However, this discovery went unnoticed until the end of 
the 1980s when the potential uses of BODIPY were realized as possible fluorescent probes.81, 82 
This idea however was not implemented until 1989 when BODIPY analogues were first used for 
biological labeling. 83 Over the past two decades, enthusiasm for this class of molecule has grown 
significantly as BODIPY was recognized to be a generally more photostable than fluorescein; 
another green fluorescent dye. By 2006, over 700 patents and 1000 journal articles were 
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published with regard to the synthesis and application of BODIPY based dyes. 84 Many BODIPY 
analogues have high quantum yields and are relatively stable both thermally and 
photochemically. Moreover, possesing a high molar extinction coefficient, great solubility 
profiles and environment-independent fluorescence make BODIPY fluorophores an ideal 
alternative for molecular labeling.85 
The IUPAC name for BODIPY is 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene, which is 
derived from the skeletal structure of indacene (Figure 2-1). Regarded as "porphyrin's little 
sister" the numbering system are analogous when referring to BODIPY. This is especially true at 
the 8-position, often referred as the meso position. The meso, 3- and 5- positions are popular sites 
for derivatization. In general, the majority of BODIPY based dyes are substituted due to the 
instability of the dipyrromethene precursor, thus, the fully unsubstituted BODIPY core was yet 
to be synthesized until 2009 by three independent groups, including US. 86-88 
Indacene 
"meso" 
"beta" ,.............. 
7 8 ~ 
6~ 
\--N'B/NJJ 
5 F' 4 'F 3 "alpha" 
BODIPY 
Figure 2-1 4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene skeletal structure. 
2.2 General synthesis of BODIPY 
BODIPY derivatives were first prepared through their precursors, dipyrromethenes. In 
the presence of an acid, a condensation reaction between pyrroles 45 and pyrrole-2-
45 
· _ carboxaldehyde 44 will generate the desired dipyrromethene. This type of reaction is frequently 
seen in porphyrin chemistry and is often referred to as the MacDonald coupling reaction. 89 
However, alkyl substitutions of pyrroles at the a-position are usually employed to increase the 
stability of the dipyrromethene intermediate. Furthermore, such substitutions deter the 
possibilities of further polymerization or porphyrin formation. Subsequent complexation with 
boron trifluoride diethyl etherate in the presence of a base such as triethylamine or 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) gives corresponding BODIPY product 46 (Scheme 2-1). 
This synthetic methodology is particularly advantageous for the synthesis of asymmetric 
BODIPY derivatives, in fact, many BODIPY analogues used for labeling biomolecules are 
synthesized in this manner. 83 
R2 R3 )( W R3 R4 ~H r ~ i ii + -----.. R2 ~ NH N=--- Rs -----.. R2 Rs R1 N N ~ 0 R1 ~ R1 
44 45 46 
Scheme 2-1: Reagents and Conditions: i) HBr, CH2Ch; ii) NEt3, BF3·Et20. 
Asymmetric BODIPY analogues are useful if conjugation methods demand the linking of the 
fluorophore with the desired molecule at any of the Rl to R6 positions of compound 46. 
Alternatively, functional groups can be introduced at the meso-position to allow for labeling. In 
the latter approach, condensation of pyrroles 47 with acyl chloride 48 will yield the 
dipyrromethene hydrochloride salt 49 that will vary in stability depending on the substitution. 
Subsequent complexation with BF3·Et20 is required for the formation of the BODIPY core 50 
(Scheme 2-2). 
46 
W R4 R3 R2 R3 0 )i ~CI i -----.- R R . Hel -----.... R2 R2 + 2 ~ NH N....... 2 R1 N 
R1 R1 R1 
47 48 49 50 
Lastly, aldehydes may be used as an alternative to acyl chlorides as the highly 
electrophilic carbonyl substrate. However, the two approaches give different intermediates in 
BODIPY synthesis. When aldehydes are used, the more stable dipyrromethanes 53 are formed, 
instead of the unstable dipyrromethene. The drawback with this method is that the 
dipyrromethane intermediate needs to be oxidized to the dipyrromethene prior to complexation 
(Scheme 2-3). However, this synthetic strategy is still routinely used due to the chemical stability 
of dipyrromethanes, thus, broadens the scope and chemical alternatives to BODIPY conjugation 
strategies. 85 
w 
~ 
R2 R3 0 
R~H i R2 R2 )J -----... R2 ~ NH HN # R2 ----... + 
R1 N 
R1 R1 R1 
51 52 53 54 
Scheme 2-3: Reagents and Conditions: i) (a) 2,3-Dichloro-5,6-dicyano-l,4-benzoquinone (DDQ), (b) 
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2.3 Fluorescent Properties of BODIPY 
The rigid frame of the BODIPY core leads to extraordinarily high fluorescent quantum 
yields through conjugation of n-electrons that exists along the backbone. By modifying this 
conjugation system, possible disruption or enhancement of quantum yields would be observed.90 
Interestingly, depending on the nature of the extended conjugation system by various meso-aryl 
substitution, the BODIPY s often exhibit a significant reduction in fluorescent quantum yields 
(Figure 2-2). 
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CH2Ch <I> 0.36 
Amaxabs 508nm 
Amax emiss 524nm 
56 
CH2Ch <l> 0.94 
Amax abs 50 Inm 
Amax emiss 512nm 
Figure 2-2 Fluorescent effects of meso-aryl substituted BODIPY. Reduced quantum yields (<I» are 
observed in unsubstituted meso-aryl BODIPYs 
However, if the aryl groups and the B-positions of the BODIPY backbone are substituted 
with various alkyl groups 56, then high fluorescent quantum yields is restored. Such alkyl 
substitutions are believed to restrict free-rotation and "lock" the aryl substituent orthogonally to 
the BODIPY core.85 Furthermore, aryl substitution at the meso-position does not substantially 
alter the maximal absorption and emission profile. Substitution at the a-positions of BODIPY is 
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more effective in shifting the absorption and emission wavelengths. 91 , 92 As can be seen from 
Figure 2-3, extended a-substituted conjugation systems will shift the maximal emission 
wavelength enough to cover the majority of the visible spectrum.93 
OH o 
o 0 
~O 0 HN{-J~~ 
57 o=<=t 59 
58 MeO 
o 
60 
o=tt 
Structure # Analogue 
1 57 BODIPYFL 
2 58 BODIPYR6G 
3 59 BODIPYTMR 
4 60 BODIPY 581/591 
5 61 BODIPYTR 
6 62 BODIPY 630/650 
Wavelength (nm) 7 63 BODIPY 650/665 
Figure 2-3 Current BODIPY fluorophores that display varying fluorescence (Spectrum and reproduced 
structures taken from Invitrogen's Molecular Probes: The Handbook).93 
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Other interesting methods for extending the conjugation system include replacing the 
fluorine atoms (Figure 2_4).94-97 Replacements such as alkoxy, aryl, ethynyl aryl , and ethynyl 
from fluorines have surprisingly stable characteristics and the loss of fluorescence is usually 
minimal, thus, indicating that fluorines are not obligate substituents for core fluorescence. The 
various substitution approaches demonstrates the versatility of BODIPY to be derivatized such 
that it may meet the individual demands. 
Rs = Aryl, Alkyl 
Figure 2-4 Exchange of core fluorines to extend BODIPY functionalities. 
2.4 Oligonucleotide labeling using BODIPY 
Currently, labeling of oligonucleotides has been used extensively in many applications 
such as flow cytometry, DNA sequencing, polymerase chain reaction, and genetic analysis. 
Overall, BODIPY -based fluorophores are relatively small in nature and electronically neutral, 
thus are advantageous and compatible with many post-analysis protocols such as gel 
electrophoresis.9s, 99 The polarity and pH of buffer solutions do not affect the fluorescence or 
distort the structural integrity of the BODIPY fluorophore, therefore will not disrupt or alter the 
migration rates of oligonucleotide fragments. IOo BODIPY -conjugated oligonucleotides are among 
the brightest derivatives and are commonly used in DNA sequencing and nucleic acid 
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hybridization studies. 101 There are two well known methods for conjugation of fluorophores to 
oligonucleotides: post-synthetically and enzymatically. 
Post-synthetic incorporation of fluorescent dyes IS a less common approach for 
oligonucleotide labeling. Conjugation mechanisms are usually non-specific as the users have no 
direct control over where the fluorophores are incorporated, thus small varying fluorescent 
intensities are observed. Nevertheless, this approach has found some use in various hybridization 
assays and analysis. One such example is the labeling of oligonucleotides for uses in 
comparative genomic hybridization (CGH).102, 103 CGH is a technique that allows for global 
analysis of genomes with varying gains and losses of DNA sequences found in solid-tumors.104 
Post-synthetic conjugation methods are advantageous since enzymes are not needed to facilitate 
incorporation of these fluorophores and because conjugation reactions are relatively fast 
(approximately 15 minutes for fragments with less than 1000 base pairs). One current kit that is 
commercially available uses a platinum-dye complex that will form a stable adduct with the N7-
amino groups of guanine (Figure 2_5).93 
+ 
N 
N 
o N ·. 
N 
NH 
NNHJ1 
Figure 2-5 Post synthetic labeling of oligonucleotide using platinum-dye adduct of N7-amino groups of 
guanine (figure taken from Invitrogen's Molecular Probes: The Handbook). 93 
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Another post-synthetic protocol for the incorporation of fluorophores is to use amine or thiol 
reactive probes that will label the amine- or thiol- modified oligonucleotides. By derivatizing 
oligonucleotides at the 3' - or 5' -end with amines or thiols, conjugation will only occur once at 
these reactive sites, thus, leading to uniform distribution of the fluorophore . In this regard, 
BODIPY fluorophores are modified to recognize these active 5' -amino oligonucleotides by 
bearing the succinimidyl ester tether to allow conjugation (Figure 2-6). 
o 
u .... .. . . ~. -C-NH~ 
Figure 2-6 Oligonucleotide labeling using reactive 5' -amino derivatives (figure taken from Invitrogen's 
Molecular Probes: The Handbook). 93 
Enzymatic conjugation methods are slightly more popular as it gives the users more 
control to when and where the fluorophore will be incorporated into the oligonucleotide 
sequence. The method of choice is to use a pre-labeled nucleotide triphosphate that is chemically 
modified to have the BODIPY fluorophore attached (Figure 2-7). This molecule would then be 
used to act as a substrate for polymerase chain reaction (PCR). Therefore, incorporation of the 
BODIPY is carried out enzymatically and no post modifications are necessary. These pre-
modified nucleotide triphosphates are commercially available and are known as ChromoTide.93 
However, the disadvantage with this method is the relative bulkiness of the ChromoTide, thus, 
incorporation during PCR may sometimes be incomplete. The sterically hindered molecule 
inhibits enzymatic binding for oligonucleotide labeling. Furthermore, if the ChromoTide is 
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1 
.1 
integrated within the sequence and not at the terminal sites, hybridization of the oligonucleotide 
sequence is further hindered. 
~~N~O 
o H ~ NH 
I~ 
o 0 0 N 0 
II II 11-0 HO-P-O-P-O-P-O 1 1  0 
0- 0- 0-
OH 
Figure 2-7 ChromoTide substrates for PCR (Reproduced structure from Invitrogen's Molecular Probes: 
The Handbook).93 
To alleviate these shortcomings, strategies involving conjugation of fluorophores have 
taken the best of both post-synthetic modification and the enzymatic procedures. Recently, newer 
methods for conjugation involve a two step process that yields greater conjugation efficiency and 
uniformity. First, PCR reactions are used to incorporate the amino-modified nucleotide 
triphosphates which are similar to the ChromoTides, but much less bulky. Thus, enzymatic 
binding is significantly enhanced. Once the PCR is complete, a second step of post-synthetic 
conjugation will label any incorporated amino-modified nucleotides using the amine-reactive 
fluorescent dye (Figure 2_8).105 
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Step 1 
polymerase 
EnzymattcaUy incorpomte 
aminoaJlyl~dUTP 
Step 2 
label amine groups using 
readive dyes or haptens 
Figure 2-8 Efficient two step process of oligonucleotide labeling (figure taken from Invitrogen's 
Molecular Probes: The Handbook).93 
2.5 General perspectives of oligonucleotide labeling and objectives 
Synthesis of labeled oligonucleotides has thus far realized much of its success through post-
synthetic labeling or enzymatic incorporation of fluorescent dyes. Syntheses of many short 
oligonucleotides have been labeled in this manner. However, many PCR techniques require 
primers that initiate the polymerase reaction; therefore, if these primers were already pre-labeled, 
there would be no need for post-synthetic modification. Post-synthetic incorporation of 
fluorescent dyes also requires additional steps of purification to remove any excess reagents. 
However, this would not be the case if the fluorophore were already incorporated into the primer 
and were ready for PCR extensions. Furthermore, 5' -BODIPY labeled primers would not 
interfere with the binding of polymerases during peR. 
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One method for the synthesis of fluorescently labeled oligonucleotides involves the 
phosphoramidite chemistry-based solid phase synthesis. Similar to chemically synthesizing 
nucleoside phosphoramidite building blocks, the same chemical methods may be applied to 
assemble a BODIPY-based phosphoramidite. Therefore, upon completing the desired 
oligonucleotide sequence of interest, the DNA synthesizer will continue on with one more cycle 
to incorporate the BODIPY fluorophore at the 5' -end of the sequence. Assuming that the 
coupling reactions for these BODIPY phosphoramidites behave similarly to DNA 
phosphoramidite building blocks, it would be possible to achieve yields of greater than 99% for 
fluorophore incorporation. Since BODIPY may be derivatized to have emission profiles that 
cover the entire visible spectrum, it is in principle feasible to produce a series of stable 
fluorophores of any color and attach it to an oligonucleotide sequence of interest. Therefore, the 
goal of this project is to explore various chemical strategies that allow for the synthesis of a 
suitable BODIPY-based phosphoramidite that may be integrated into the solid phase DNA 
synthesis. Thorough testing of compatibility and stability of these BODIPY phosphoramidites 
were pursued to ensure viability and to obtain high quality labeled oligonucleotides. 
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Chapter 3 - Results and Discussion 
Optimization of solid phase synthesis of RNA using the Cpep chemistry 
3.1 Overview of solid phase synthesis of RNA 
It is clear that solid phase synthesis of RNA is not as efficient as DNA with respect to 
step-wise coupling time and coupling efficiency. As can be seen from Table 3-1, when 
comparing the time requirement of each step within a synthesis cycle, the total time of each RNA 
cycle lasts almost twice as long as that of the DNA cycle. Of the four steps in a cycle, only two 
would seem viable for modifications to reduce the total synthesis cycle: detritylation and 
coupling. There is a tremendous difference between the coupling time of RNA and DNA, 
therefore, the development of an alternative methodology that could enhance the step-wise 
coupling time would significantly reduce the overall synthesis time of each cycle. By 
derivatizing the phosphitylation procedures through the use of various alternative amino-
phosphoramidites, there may be some potential to reduce the coupling time and perhaps even 
improve the coupling efficiency. 
Table 3-1 Time required for step-wise chemical reaction and delivery to solid supports at 1.0 ~mole scale. 
Protocol 
Coupling 
Oxidation 
Total 
DNA (sec) 
20 
32 
756 
RNA (sec) 
600 
32 
1336 
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The second step in which optimization is a possibility is the detritylation step. By 
attempting to enhance the overall quality of the products, it would also lower the time required to 
detritylate the 5' -protecting group due to reduced acid exposure and potential degradation. There 
has been literature precedence for alternative 5' -protecting groups that are more acid-labile than 
the DMTr group.106 The use of a more acid-labile protecting group would potentially reduce the 
detritylation step to a more reasonable time frame. However, careful manipulations should be 
considered since the use of a protecting group that is too sensitive to acid may result in its 
premature loss during the coupling step where an activator, typically a weak acid as well, is 
needed for phosphoramidite activation. If this were to occur, a double addition of the 
phosphoramidite building block would be observed. 
3.2 Improving coupling efficiency 
By screening phosphoramidites derived from various secondary amines, a kinetic model 
study in solution will determine which derivative may yield greater reactivity. By determining 
the consumption rate of starting material 64-67 and the generation of the uri dine dimer 69 
products over time, establishing the half-life of the phosphoramidite derivatives would be 
achieved (Scheme 3-1). Some of the potential secondary amines that were used for the synthesis 
of its corresponding phosphochloridite were diethylamine, piperidine, and pyrrolidine (Figure 3-
1). 
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1 mol eq. 
64: NRR' = Diisopropyl 
65: NRR' = Diethyl 
66: NRR' = Piperidine 
67: NRR' = Pyrrolide 
1.25 mol eq. 
68 
Scheme 3-1: Reagents and conditions: i) CH3CN, 1H-tetrazole. 
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Figure 3-1 Derivatives of 2' -Cpep ribonucleosides from various amino-phosphochloridites. 
Since phosphotriesters are highly unstable species, manipulations of the reaction mixture 
may lead to ambiguous or inaccurate interpretation of the data. Therefore, the study was carried 
out in an NMR tube and the constant acquisitions of phosphorous spectra at specific time 
intervals allowed for real time analysis without interference from external sources. Furthermore, 
to standardize the consumption of starting material and the development of the products, an 
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._ internal standard, O,O'-diethyl-S-phenylphosphorothioate 77, was used (Scheme 3-2). Figure 3-2 
demonstrates the loss of the starting material 31 P NMR signal at approximately 145 ppm and the 
appearance of the product signalat 139 ppm as the reaction proceeds. 
0 
EtO ... p .... OEt 
+ <N-SPh ~ O,p .... OEt I EtO'" 'SPh OH 
0 
75 76 77 
Scheme 3-2: Reagents and conditions: i) CsHsN, 16 h . 
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Figure 3-2 Overlay of reaction mixture after specific time intervals. 
It can be seen from Table 3-2 that the standard N,N-diisopropyl phosphoramidite 64 is the 
least reactive with a half life of 15.8 min for the coupling reaction, while pyrrolidino 
phosphoramidite 67 is the most reactive with less than 0.25 min. Despite the fasting coupling 
reactions with pyrrolidino- and piperidino phosphoramidites, purification of corresponding 
monochloridite (i.e. 72 and 73) proved difficult. Both chloridites undergo thermo decomposition 
during distillation. N,N-Diethyl-O-cyanoethylphosphochloridite, on the other hand, is stable 
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· _ enough to allow for purification by distillation. In addition, 5' -O-dimethoxytrityl-2' -O-Cpep 
uridine 3' -N,N-diethyl-O-cyanoethyl phosphoramidite is stable for over 2 months as a dry solid 
at -8°C, and stable for at least two weeks in dry acetonitrile at room temperature. Considering 
both reactivity and stability, the rest of this work compared N,N-diethyl- and N,N-diisopropyl-O-
cyanoethylphosphochloridites in solid phase RNA synthesis. 
Table 3-2 Calculated half-lives of 5' -O-dimethoxytrityl-2' -O-Cpep uridine 3' -phosphoramidites derived 
from various secondary amines. 
Compound Diisopropyl Diethyl Piperidine Pyrrolidine 
Phosphoramidite Phosphoramidite Phosphoramidite Phosphoramidite 
64 65 66 67 
As can be seen from Scheme 3-3, both the 5' - and 3' -hydroxy functions may be protected 
with the use of 1,1,3,3,-tetraisopropyldisiloxy chloride to selectively incorporate the 2' -Cpep 
protecting group (as in 80). Subsequent phosphitylation using the desired diethyl or diisopropyl 
phosphochloridite gave the corresponding 3' -phosphoramidites for solid phase synthesis. Since 
phosphitylation procedures are highly susceptible to hydrolysis, careful handling during this step 
is required to prevent formation of 3' -phosphoramidate by-products. Even though these 
impurities are not reactive and most likely will not interfere during solid phase synthesis 
procedures, it may change the overall quality of the solid phase synthesis products. 
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Scheme 3-3: Reagents and conditions: i) (i-PrhSi(Cl)OSi(i-Prh(Cl), CsHsN; ii) CF3COOH, CH2Ch; iii) 
Et4N+F-, CH3CN; iv) DMTr-Cl, CsHsN; v) (i-PrhNEt, 70 or 71, THF. 
3.3 Solid phase synthesis and comparison of N,N-diisopropyl and N,N-diethyl 
phosphoramidites 
From the previous solution phase model study, N,N-diethyl phosphoramidite would seem 
to be the most promising candidate for solid phase RNA synthesis, however, chemistries applied 
to a solid support often yields vastly different results. Nevertheless, moving from solution phase 
to solid phase synthesis, the trends would at least hold true, that is, diethyl phosphoramidite 
would provide greater coupling efficiency than diisopropyl phosphoramidite. Over the course of 
these studies, a myriad of variables were tested and well over 100 samples were analyzed in 
search of enhancing the overall coupling efficiency. To summarize the findings, each individual 
discovery will be described in one of three categories: activator, solid support, and technical 
alterations. 
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Optimization strategies were carried out in a progressive manner. After testing a specific 
variable of interest, results were carefully analyzed to determine whether it was an improvement 
or not. If improvements were observed, these changes would be kept and applied to the next set 
of trial runs. The advantage with the progressive process relies on selecting the best variables of 
each individual experiment to arrive at the final theoretically optimal methodology. 
Unfortunately, the disadvantage is that this may not arrive at the best method since compatibility 
of each variable plays a major role in determining the optimal procedure. Initially, standard solid 
phase protocols of RNA synthesis, i.e. TBDMS based chemistry, were compared to the Cpep 
chemistry to determine the level of compatibility before any changes were made (Table 3-3). If 
the standard TBDMS building blocks were used, it would be expected that approximately 98% 
step-wise coupling yields and an overall product yield of ca. 83% for a U 10 would be achieved. 
However, when Cpep building blocks were used, the overall yield was 45.7% with an average 
stepwise yield of91.6%. 
Table 3-3 Standard cycle conditions for solid phase synthesis of RNA. 
Deblocking Solution TCA (3 % in dichloromethane) 
Coupling Activator IH-Tetrazole (0.45 M in acetonitrile) 
Step-wise coupling yields play an incredible role in the overall quality of the final 
product and carries exponential repercussions if poor yields are obtained. As indicated from 
Figure 3-3, average step-wise coupling yields of 90% would result in near complete loss of any 
product material for the synthesis of a 50-mer oligonucleotide. Synthesizing the same 50-mer at 
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· _ 95% step-wise yield would give only 10% of the desired oligoribonucleotide. Even differences 
between 98% and 99% yield after 49 cycles is substantial; 1 % yield difference per cycle led to 
greater than 20% loss in full length product. Therefore, with respect to the optimization process, 
even an 0.5% increase would be a significant improvement, especially with yields that begin to 
reach past 98%. 
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Figure 3-3 Synthesizing sequences with a specific step-wise coupling yield results in exponential loss as 
longer sequences are made. 
3.3.1 Choice of Activators 
The choice of activator would be the most significant factor in coupling efficiency. In the 
past, the standard choice of activator for solid phase synthesis of oligonucleotides is IH-
tetrazole, however, many industries and independent research groups are slowly moving away 
from using IH-tetrazole. There are distinct disadvantages with using IH-tetrazole especially 
when large scale oligonucleotide synthesis is required. IH-Tetrazole is known to be a potential 
explosive, hygroscopic, and sparingly soluble in acetonitrile. Its limited solubility in acetonitrile 
may pose a problem due to blockage of the DNA synthesizer's inner tubing. Furthermore, due to 
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· _ its inherent hazards, accessing commercially available IH-tetrazole in Canada is tremendously 
difficult. Therefore, alternative activators are explored for their potential uses in the solid phase 
synthesis. Candidates that had generated enough promising preliminary data were further tested 
for their viability in the final protocol. Activators that were extensively studied and their 
respective cycle conditions are listed in Table 3-4 and Table 3-5, respectively. 
Table 3-4 Overall yields for the synthesis of a U lO using different activators and concentration. 
Activator Concentration in 
Acetonitrile (M) 
Diethyl 
Phosphoramidite 
0/0 
Diisopropyl 
Phosphoramidite 
% 
Table 3-5 Cycle conditions for individual activator used. TCA (30/0 in dichloromethane) were used as the 
deblocking solution in all sample data. 
Activator Concentration in Detritylation Coupling Time 
Acetonitrile (M) time (s) (s) 
As can be seen from Table 3-4, with IH-tetrazole as activator, major differences were seen in 
the overall yields between 2' -Cpep protected 3' -N N-diethyl and 3' -N,N-diisopropyl 
ribonucleotides. Clearly, the enhanced reactivity of N,N-diethyl- over N,N-diisopropyl 
phosphoramidite resulted in greater coupling efficiency. Over the course of these experiments, it 
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· _ was noticed that diethyl phosphoramidites do not usually perform as well as diisopropyl 
phosphoramidites when more concentrated activators were used. This is possibly due to the 
relative instability of diethyl phosphoramidites as a trade off to enhanced reactivity. Therefore, a 
decision was made to keep all activators to a concentration of 0.25 M in an attempt to promote 
diethyl phosphoramidites as a potentially new building block in RNA synthesis. In this regard N-
phenylimidazolium triflate and 5-benzylthio-IH-tetrazole did not perform as well as 5-ethylthio-
IH-tetrazole. Using 5-ethylthio-lH-tetrazole at a concentration of 0.25 M achieved an overall 
yield of 70.4% with N,N-diethyl phosphoramidite. 
3.3.2 Choice of Solid Supports 
The presence of the 2' -protecting group greatly increases the steric bulk of the 
ribonucleotide building block and inadvertently hinders the coupling process. As the 
oligonucleotide extends on the solid support, this effect is further enhanced and noticeable 
differences in yield may be observed as the pores restrict access of incoming building blocks. In 
theory, greater porosity of solid supports enhances the sustainability of longer sequences of 
oligonucleotides. Another factor that affects solid supports is the amount of initial nucleoside 
loaded. Solid supports of higher loading of the initial nucleoside are often "crowded" therefore 
- the first few cycles in the synthesis of oligoribonuc1eotides may be hindered. This is once again 
especially true when the 2' -protecting group contributes to the majority of the effective steric 
bulk. 
Testing of each solid support revealed very little differences in the final yield. It is highly 
probable that U 10 is too short to be useful in the determination of the effectiveness of individual 
types of solid supports. A thorough comparison would perhaps require a much longer sequence 
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.. to be used. Future experiments will be performed when cycle conditions are finalized. Therefore, 
the 3-Prime CPG with regular loading (35 ~mole/g) and high porosity (1085 A) were used to 
alleviate any possible steric stress applied by the 2' -Cpep protecting group (Table 3-6). 
Table 3-6 Various types of solid supports were used to determine their effects on coupling yields. 
Solid Support Supplier Porosity (A) 
3.3.3 Technical optimization and finalization 
As mentioned above, each cycle of the solid phase synthesis is broken into four steps: 
detritylation, coupling, capping, and oxidation. There is little room for technical changes with 
respect to capping and oxidation, however, the detritylation and coupling steps, were modified 
such that the conditions may be tailored to fit the new chemistry. Three main aspects were 
explored, sparging, base wash, and coupling time. Theoretically, these steps have been 
previously optimized for individual DNA synthesizer and are generally accepted by the industry 
and most research groups. Therefore, drastically changing the programming sequence may 
hinder acceptance among the scientific community regardless of the success. 
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· _ 3.3.3.1 Sparging 
Sparging is a technique where short bursts of inert gas is flushed into the reaction 
column, thus, agitating and mixing the suspension of solid supports. Although this technique is 
uncommon in the synthesis of DNA due to their already highly efficient coupling yields, this is 
not the case for RNA synthesis. Thus, it is common to agitate the reaction column through 
sparging in solid phase synthesis of RNA. There are two standard protocols built into the ABI 
3400 DNA synthesizer for RNA synthesis: 11lmole and O.2llmole (Appendix Al and A2). There 
are no major differences between the two procedures except the amount of reagents delivered to 
the column depending on the scale of the synthesis. However, when synthesizing RNA at the 1 
Ilmole scale, regular loading CPG are often tightly packed within the enclosed column of fixed 
volume. 
The addition of the sparging procedure allows the solid supports within the column to be 
mixed and exposed to the reaction solution more readily, thus, allowing more effective coupling 
reactions. From Table 3-7, an overall yield improvement of approximately 5% was observed by 
sparging the reaction column with argon. More specifically, argon was delivered into the 
reaction column in short bursts (1 sec) at 50% and 75% of total incubation time. (e.g. If the 
coupling time was a total of 2 min, argon would be delivered at 60 sand 90 s.) 
Table 3-7 Effects of sparging with argon to the reaction column. 
Diethyl Diisopropyl 
Pho oramidite Pho oramidite 
Sparging 62.8% 66.9% 
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3.3.3.2 Base wash 
2' -Cpep protecting group is a unique ketal based system in that its rate of hydrolysis is 
virtually independent of pH from 0.5 to 3.0. This property is attributed to the positively charged 
aryl-piperidinium system at this pH range which acts as an electron withdrawing group, hence, 
the observable resistance in acid-promoted hydrolysis. During detritylation, trichloroacetic acid 
would most likely protonate the Cpep group (as in Figure 3-4). It is probable that the positive 
charge on the piperidine ring may interfere with the activation of phosphoramidite by a weak 
acid due to electronic repulsion, thus leading to a reduced coupling efficiency in the following 
cycle. 
Figure 3-4 Formation of the piperidinium ion after during the detritylation step. 
Phosphoramidite building blocks are activated by treatment with a weak acid to allow 
protonation of the phosphoramidite. Using the standard IH-tetrazole activator as an example, this 
compound not only acts as a proton donor, it also participates in nucleophilic displacement of the 
diisopropylamino group.107 This activated tetrazolide intermediate is quickly consumed by 
reacting with the incoming 5' -hydroxyl function of the extending oligonucleotide (Figure 3-5 A). 
The protonation process is quick and reversible, however, when the adjacent piperidine of 2'-
Cpep protecting group is protonated during the detrytilation step, this positive charge would 
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· _ likely hinder the protonation, and thus activation, of phosphoramidites at the 3' -position (Figure 
3-5 B). Consequently, coupling efficiency would likely be compromised. 
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Figure 3-5 A: Mechanism for the coupling reaction when activated by tetrazole. B: The formation of two 
positive adjacent ions is unfavorable which will hinder the formation of the tetrazolide intermediate. 
To circumvent this problem, the CPG within the reaction column was washed with 5% 
pyridine in dry acetonitrile to neutralize piperidinium that is likely formed during the 
detritylation step. This additional washing step was to be implemented after detritylation and 
prior to the next coupling reaction. By far, this modification to cycle conditions led to the most 
significant improvement on the overall final yield as can be seen in Table 3-8 (cycle conditions 
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_ in Table 3-9); especially for the diethyl phosphoramidite building blocks a 12% increase was 
observed. 
Table 3-8 Effects of washing the reaction column with 5% pyridine in acetonitrile. 
Base Wash 
Diethyl 
phosphoramidite 
79.4% 
Diisopropyl 
Phosphoramidite 
73.7% 
Table 3-9 Specific cycle conditions for solid phase synthesis of RNA with and without base wash. 
Deblocking Solution TCA (3 % in dichloromethane) 
Coupling Activator 5-Ethylthio-1H-tetrazole (0.25 M in acetonitrile) 
3.3.3.3 Coupling time 
RNA coupling time is the longest step in solid phase synthesis of oligoribonucleotides, 
although the incubation time will vary depending on the chemistry involved, the default reaction 
time frame is 600 sec. From the solution phase model study of different phosphoramidite 
derivatives, it is expected that diethyl phosphoramidite will outperform diisopropyl 
phosphoramidite because of its greater reactivity, assuming that the trend from solution phase 
holds true, that is, diethyl phosphoramidite is much more reactive than diisopropyl 
phosphoramidite. Reducing the coupling time to 20 sec perhaps may have been too ambitious, 
therefore, the two coupling time that were more reasonable was 120 sec and 30 sec. From Table 
3-1 0 (cycle conditions in Table 3-11), diethyl phosphoramidite showed a minor increase in 
overall yield when the coupling time was reduced from 120 sec to 30 sec. However, diisopropyl 
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'. phosphoramidite was adversely affected by the shorter coupling time, as a result, lower overall 
yields were obtained. 
Table 3-10 Effects of reducing the coupling incubation period. 
30 sec 82.0% 68.1 % 
Table 3-11 Specific cycle conditions for solid phase synthesis of RNA at 120 sec and 30 sec coupling 
time. 
Deblocking Solution TCA (3% in dichloromethane) 
Sparging On (Argon) 
3.3.4 Combining all changes that enhanced overall yield 
Further testing was done to determine the compatibility of each individual factor that may 
affect coupling yields. For example, when applying sparging and base wash to diisopropyl 
phosphoramidites at 120 sec coupling time, in general, it performed slightly better than diethyl 
phosphoramidite. Conversely, when the same conditions were applied to diethyl 
phosphoramidite, but the coupling time was reduced to 30 sec, diethyl phosphoramidite yielded 
better results. Once again, it is highly probable that the enhanced reactivity of diethyl 
phosphoramidite also translates into greater instability in solution. Nevertheless, combining all 
favorable tested variables together at 30 sec coupling time yielded much higher overall yields 
and is almost comparable to solid phase synthesis of DNA. From Table 3-12 (cycle conditions in 
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_ Table 3-13), there was almost a 30% improvement of yield for the synthesis of D IO, while 
reducing the coupling time to 30 sec. 
Table 3-12 Final synthesis of U 10 and comparison after optimization. 
Final Protocol 91.1% 87.6% 
Table 3-13 Cycle conditions for solid phase synthesis of RNA after combining favorable optimization 
procedures (For specific programming details see Appendix A3). 
Deblocking Solution TCA (3 % in dichloromethane) 
Coupling Time 30 sec 
Base Wash On (5% pyridine in acetonitrile) 
3.4 Choice of the 5' -protecting group 
Consideration was also given to a possible alternative 5' -protecting group that is more 
acid labile than DMTr. Such an alternative might offer two advantages when used in conjunction 
with the 2' -Cpep group. The first obvious advantage is to reduce the overall detritylation time 
without losing the integrity or quality of the RNA sequence. Secondly, even though there has 
been no evidence to support significant loss of 2' -Cpep during detritylation, the 2' -Cpep 
protecting group is nevertheless a ketal based system, therefore is acid-labile. If the detritylation 
time is reduced, this would also inadvertently reduce the acid exposure time to the 2' -Cpep 
group, as a result, loss of Cpep may be further suppressed. 
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One candidate that has demonstrated some promising properties is the 2,7 -dimethyl-9-
phenyl-xanthen-9-yl (DMPx) group (Scheme 3-4). In a recent study performed in this lab 
(unpublished results), DMPx and 9-phenyl-xanthen-9-yl (Px) were shown to be about three times 
more acid labile than DMTr when dichloroacetic acid was used in the presence of pyrrole as a 
cation scavenger. It was also shown recently in a patent that the DMPx precursor/08 i.e. 2,7-
dimethyl-9-phenyl-xanthen-9-ol, can be readily obtained via a Friedel-Craft reaction instead of a 
Grignard reaction due to the ready availability of precursor reagents, i.e. p-tolylether and U,U,U-
trichlorotoluene. Consequently DMPx-Cl is less costly than Px-Cl. The following work was 
therefore undertaken to determine the minimal conditions that are required for the removal of 
DMPx- and DMTr-groups in solid phase synthesis. As a model study, a homo oligomer, TlO, was 
used. The synthesis of corresponding thymidine phosphoramidites is illustrated in Scheme 3-4. 
Thymidine 83 was first protected at the 5' -OR with the desired DMPx- or DMTr-group in 
pyridine and was subsequently phosphitylated using N,N-diisopropyl phosphochloridite to obtain 
the 5' -protected phosphoramidite thymidine. 
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Scheme 3-4: Reagents and conditions: i) DMTr-Cl or DMPx-Cl, C5H5N; ii) (i-Pr)2NEt, 70, THF. 
Solid phase synthesis of T 10 oligomers at varying detritylation times with both 
trichloroacetic acid (TCA) and dichloroacetic acid (DCA) were carried out. Each individual 
oligonucleotide sample was cleaved from the solid support by treatment with ammonium 
hydroxide at 55°C overnight and was analyzed using anion exchange HPLC. As can be seen 
from Table 3-14, when the detritylation time was reduced to 20 seconds while using the TCA 
(3%), the HPLC profile obtained suggested that approximately 99% stepwise coupling yields 
were observed. The transition from TCA to DCA generated significant differences in the 
synthesis of T1O. Results would indicate that using DCA (3%) would continue to yield the 
synthesis of a full length T 10 at 110 sec of detritylation. However, when the acid delivery time 
was reduced to 20 sec, it would seem that the overall yield dropped to 71 % for DMTr and 840/0 
for DMPx. As the time increased to 40 sec, the overall yield began to rise to 86% for DMTr and 
87% DMPx. It is possible at this point that the drop in yield was not due to exposure to the actual 
acid. The mechanical set up of the ABI 3400 DNA synthesizer requires 15-20 s for the acid 
74 
. _ solution to be delivered to the column. Therefore, 20 sec of acid delivery time in the detritylation 
step may not be long enough for acid exposure; it would therefore be advisable to have at least 
30 sec of acid delivery time regardless of the choice of acid and acid concentration. 
Table 3-14 Overall yields for the synthesis ofa TlO using different acids and concentration. 
Yield (%) 
TCA (3) 20 88 88 
DCA (3) 20 71 84 
DCA (3) 40 86 87 
DCA (1.5) 40 77 86 
DCA (0.5) 30 1 49 
As the concentration of DCA was reduced to 1.5%, however, it became obvious that the 
5' -DMTr group cannot be removed as efficiently as DMPx. The overall yield for the synthesis of 
a full length TlO were as low as 62% for DMTr at 30 sec and even when the time was increased 
to 50 sec, the overall yield was only 79%. Within the same time frame and conditions, however, 
use of DMPx as 5' -protecting group gave constantly high yielding full length TlO oligomers (at 
approximately 87%). Lastly, when the DCA concentration was reduced to 0.5% with delivery 
time of 30 sec, use of DMTr as the 5' -protecting group gave almost undetectable amount of full 
length TIO-mer. On the contrary, delivery of DCA (0.5%) for 50 s was sufficient to completely 
remove DMPx during the synthesis of T lO-mers. 
From these observation, it is apparent that use of DMPx as 5' -protecting group in 
oligonucleotide synthesis would allow for the use of weaker acids, and shorter acid exposure 
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_ time during the detritylation step in solid phase synthesis. Further experiments are underway to 
compare the two protecting groups in the synthesis of hetereosequences. 
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Figure 3-6 HPLC profile ofT lO using 5'-DMPx at DCA concentration of 0.5%. 
3.5 Loss of Cpep group during detritylation 
The use of 2' -Cpep in solid phase RNA synthesis has always raised concern about its 
possible loss during the detritylation step, which could cause subsequent chain cleavage or 
migration. Since the hydrolysis of ketals requires the presence of water, it is therefore of 
importance to correlate the dryness of the detritylation solution, i.e. TCA in dichloromethane, to 
the extend of loss of Cpep during detritylation. 
A model experiment was conducted involving the synthesis of a 5' -UpFluorescein* 
dimer using 3' -(6-FAM) CPG under 1.0 Jlmole RNA synthesis with 120 sec of coupling (5-
ethylthio-lH-tetrazole, 0.25 M in acetonitrile) and 11 Os detritylation time. After the first cycle 
was completed, the dimer was exposed to 18 additional cycles of alternating delivery of 3% TCA 
* 5' -UpFluorescein: italicized U indicates uridine with 2' -Cpep 76 
· for 110 sand 5% pyridine in acetonitrile for 30 sec, with thorough acetonitrile wash in between. 
It was anticipated that with the extensive exposure to acid, loss of Cpep would occur at a level 
that might be detectable by HPLC at both 260 and 490 nm after cleavage from the solid support. 
(Figure 3-7). 
20 Cycles 
,. 
o o 
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Figure 3-7 The fluorescently labeled uri dine was subjected to 19 cycles of detritylation to observe any 
loss of Cpep. 
After the above treatment, the products were cleaved from solid support with ammonium 
hydroxide treatment at 55°C overnight. The crude mixture was lyophilized and analyzed by C18 
reverse~phase HPLC. Loss of Cpep would give rise to UpF AM dimer that elutes at a much 
shorter retention time on C 18 column. HPLC trace (Figure 3-8) revealed two main peaks in ca. 
1: 1 ratio and a very small peak at a retention time of 10.7 min. After separation of the three 
fractions by C18-HPLC, the fractions were analyzed by mass spectrometry (Table 3-15). Further 
examination suggested that peak 2 (Rt 13.30 min) might have been a result of contamination 
from the FAM-CPG. To prove this, the same batch of FAM-CPG was cleaved from the solid 
support directly with ammonium hydroxide at 55°C overnight and the products were analyzed by 
C18 HPLC. As can be seen in Figure 3-9, two signals were observed, one at a retention time of 
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._ 13.3 min which matches exactly to peak 2 (Rt 13.30 min) in Figure 3-8. The second major peak 
in Figure 3-9 at 14.7 min suggests the DMTr-protected fluorescein monomer thatwas preloaded 
on the CPG. Preliminary data indicates that approximately 0.5% of 2' -Cpep was lost in this 
model experiment. However, further experiments are required to solidify this observation. 
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Figure 3-8 HPLC profile at 490 run showing one subtle peak at 10.7 min indicating 2'-Cpep lost. 
Table 3-15 Electrospray mass analysis of isolated signals from 5'-UpFluorescein. 
10.70 Loss ofCpep 812.1 812.2 
13.50 5' -UpF1uorescein 1049.2 1049.3 
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Figure 3-9 HPLC profile at 490 run of the fluorescently loaded CPG. 
3.6 Conclusion 
Modifications of 2' -Cpep protected oligoribonucleotide building blocks and solid phase 
synthesis cycles resulted in a viable methodology in obtaining high yielding and high quality 
RNA sequences using the Cpep chemistry. 3' -N,N-Diisopropyl phosphoramidites were replaced 
with the more reactive 3' -N,N-Diethyl phosphoramidite to increase coupling efficiency and 
hopes of reducing the overall coupling time. Furthermore, technical optimizations of solid phase 
synthesis cycles were pursued to maximize yields of full length RNA sequences. Various 
potential weak acids were tested to determine the most ideal activator to be used in conjunction 
with 3' -N, N-di ethyl phosphoramidite. Moreover, the use of sparging to enhance mixing, base 
wash to neutralize the piperidinium specie in Cpep, and reduced detritylation times allowed for 
high yielding synthesis of RNA sequences. Although synthesis of a homosequence was 
successful, this new method remains to be fully tested with the synthesis of heterosequences to 
determine if it is indeed truly viable. Nevertheless, with the given modifications and optimization 
of 2' -Cpep protected oligoribonuc1eotide synthesis, preliminary results suggest that this may 
possibly be a new method for synthesizing high quality RNA sequences. 
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Chapter 4 - Results and Discussion 
Synthesis of BODIPY labeled oligonucleotides 
4.1 Overview of labeling oligonucleotides with BODIPY 
It is clear that incorporating BODIPY to oligonucleotides during solid phase synthesis 
would require phosphoramidites derived from this fluorophore. A few synthetic routes were 
attempted towards this goal. Various model experimental studies were also carried out to 
examine the compatibility of the fluorophore with the conditions required for phosphitylation 
and solid phase synthesis. Consideration was given to substitutions that enhance the stability of 
the BODIPY fluorophore and the ease that allows for transformation into phosphoramidites. 
The first attempt was made to replace the nucleobase of a nucleoside with the BODIPY 
fluorophore (Figure 4-1). Starting from a ribose sugar, the attachment of a stable dipyrromethane 
to the furanose ring was envisioned to be optimal since the assembly to the BODIPY core 
structure could then be readily achieved. Furthermore, once the BODIPY core has been made, 
standard phosphitylation procedures may be carried out to give corresponding phosphoramidites. 
The advantage with this approach would be that the BODIPY nucleotide may be incorporated 
into the DNA or RNA sequence at any given position within the sequence. Moreover, the 
attachment of the fluorophore to the nucleoside is through a C-glycosydic linkage, which has 
been shown to be resistant to enzymatic degradation should the BODIPY labeled oligonucleotide 
were to be used in biological assays.109 
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Figure 4-1 General strategy envisioned for the synthesis of a BODIPY -phosphoramidite. 
4.2 Towards Glycosylation of BODIPY 
A potential synthetic route for C-glycosylation of BODIPY was with the use of the 
trichloroacetimidate chemistry. I 10 However, it was uncertain if this chemistry would be 
compatible with incorporation of the dipyrromethane. Both ribose and deoxyribose sugars are 
relatively expensive, therefore, a glycosylation model study using less expensive 
monosaccharides such as D-glucose, D-galactose, and D-mannose was developed. In order to 
prepare the sugar-derived trichloroacetimidates, all other hydroxyl functionalities were protected 
as their acetates. Treatment of 2,3,4,6-0-tetraacetyl hexoses with trichloroacetonitrile gave 
corresponding trichloroacetimidates in good yields (75-85%). 
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Scheme 4-1: Reagents and conditions: i) AC20, C5H5N; ii) NH2NH2'H20, AcOH, DMF; iii) ChCCN, 
Subsequent C-glycosylation takes advantage of the nucleophilicity of pyrrole and analogues. 
In the presence of an activator such as boron trifluoride, glycosylation occurs to form glycosyl 
pyrrole derivatives. It was envisioned that these glycosyl pyrroles may be used to assemble the 
BODIPY core via the MacDonald coupling with pyrrole-2-aldehyde. Unfortunately, this 
assembly was not possible due to the instability of the dipyrromethene intermediate. It was clear 
that further substitution methods were needed to stabilize the dipyrromethene, however, 
excessive substitutions were undesirable as they would complicate synthesis. One possible 
alternative found was a one-pot reaction with trimethyl orthobenzoate111 and pyrrole 96 to obtain 
the aryl-substituted BODIPY 102 (Scheme 4-2 A). 
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Scheme 4-2: Reagents and Conditions: i: BF3·Et20, CH2Cb. 
Unfortunately, the glycosylation reaction (Scheme 4-2B) failed to give the desired product 
103; in fact, 102 was isolated as the major product instead. It was speculated that the 
glycosylated pyrrole revealed a significantly loss of nucleophilicity, most likely due to the 
electron withdrawing effects of the acetylated glucosyl ring. Once again, an alternative synthetic 
route was needed to immobilize the precursor of the BODIPY backbone in order to assemble the 
fluorescent core. 
4.3 Synthesis of fully unsubstituted BODIPY 
During the course of this project, it came to our attention that despite the fact that the 
BODIPY fluorophore was discovered in 1968, there was not yet a method for the synthesis of the 
fully unsubstituted BODIPY, probably due to the instability of its precursor. Since chemical and 
photochemical characterization of this compound would provide a basis for further development 
83 
., of BODIPY family fluorophores, attempts were made to synthesize the fully unsubstituted 
BODIPY. While many synthetic strategies were envisioned for the synthesis of the fully 
unsubstituted BODIPY, most of them were impractical since these routes require the formation 
of the unstable dipyrromethene intermediate. Nevertheless, it was found that the dipyrromethene 
was relatively stable at temperatures below -40°C. Large quantities of the dipyrromethane 
precursor were synthesized to test a wide range of factors that could stabilize the dipyrromethene 
just enough to allow coordination with boron trifluoride (Scheme 4-3). 
Using literature procedures,112 pyrrole 96 was allowed to react with thiophosgene to 
generate dipyrrothione 104, which is then oxidized to the precursor dipyrroketone 105. A final 
reduction with sodium borohydride gives dipyrromethane in moderate yields. Ultimately, 
oxidation of dipyrromethane with 2,3,-dichloro-5,6-dicyano-l,4-benzoquinone (DDQ) at -78°C 
permits the synthesis of the dipyrromethene, that was complexed with boron trifluoride in situ 
immediately to give the fully unsubstituted BODIPY 107 for the first time. Many research 
groups have devoted their interest and time in studying the fluorescent effects of the BODIPY 
core, however, all of these methods were carried out computationally. Moreover, much of the 
collected data on the unsubstituted BODIPY's fluorescent properties were often inferred through 
their own derivatization to a more stable BODIPY molecule. I 13, 114 
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The UV/Vis absorption and fluorescent emISSIon spectra of the fully unsubstituted 
BODIPY were recorded in a solution of methanol. A maximal absorbance at 497 nm with a 
molar extinction coefficient of 64,000 M-1cm-1 and a maximal emission at 504 nm were 
observed. Using literature procedure to determine quantum yields,79 the fully unsubstituted 
BODIPY was dissolved in methanol and were used to prepare a series of five dilution aliquots. 
These five samples were analyzed for their emission and excitation profiles and a correlation plot 
was made. Using fluorescein as a standard (<I> = 0.95), preparing similar dilutions and analysis 
permits the calculated fluorescent quantum yield of BODIPY to be 0.97±0.03. The fluorescent 
life-time of this fluorophore (6.89 ns) was determined in Dr. Doug Bruce's lab at Brock 
University. 
Crystals of the fully unsubstituted BODIPY obtained from slow evaporation of hexane. 
The crystal structure, which was resolved by Dr. Hilary Jenkins at McMaster University, 
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· _ revealed that the molecule is virtually planar as is expected; however, in this case, the boron 
atom (B 1) is displaced from the mean plane by approximately 8± 1 0 .87 
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Figure 4-2 Crystal structure of un substituted BODIPY (left), Absorption and emission spectra (right). 
4.4 Glycosylation of dipyrromethanes 
Over the course of exploring various methods to synthesize the unsubstituted BODIPY, it 
became apparent that incorporation and assembly of the BODIPY fluorophore on the individual 
monosaccharides may be possible via addition of a dipyrromethane. It was found that the relative 
nuc1eophilicity of this compound was not compromised, therefore, following an analogous 
synthetic route from scheme 4-1, dipyrromethane 106 instead of using pyrrole 96 (Scheme 4-4) 
was used. This procedure was applied to D-glucose, D-galactose, and D-mannose to give 
corresponding glycosyl dipyrromethanes in good to high yields (Table 4-1 ).115 
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Scheme 4-4: Reagents and conditions: i) BF3·Et20, CH2Ch. 
Table 4-1 Glycosylation reaction yields of standard monosaccharides. 
Structure Yield Isoform 
The glycosylation reaction proceeds in a stereoselective manner for glycosyl dipyrromethane 
with the major product as the p'anomer for D-glucose and D-galactose, but a-anomer for D-
mannose, as expected. The NOEs between H-l' with H-3' and H-l' with H-5' suggest that the fJ-
C-glucosides and fJ-C-galactosides were isolated. These relationships would not be possible in 
the a-anomeric form. Conversely, mannosyl dipyrromethane was obtained with the majority of 
products as the a-C-mannoside. This was evident through NOEs between H-2' with H-2, H-3' 
with H-2, and H-3' with H-3(Figure 4-3). Subsequent treatment with boron trifluoride will allow 
for the synthesis of the fluorescent BODIPY. However, similarly to the unsubstituted BODIPY, 
low coordination yields were observed due to the instability of the dipyromethene. 
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Figure 4-3 NOE of glucosyl dipyrromethane (left) and mannosyl dipyrromethane (right). 
4.5 Ribosyl-BODIPY 
The establishment of the C-glycosylation procedure was a good starting point to move 
from D-glucose, D-galactose, and D-mannose to the D-ribose sugar. However, an alternative 
substituted 8-isopropyl dipyrromethane was used in place of dipyrromethane to enhance the 
overall stability to obtain greater yields. When comparing the preparation of unsubstituted 
BODIPY with the 8-isopropyl BODIPY in terms of final yields, the unsubstituted BODIPY were 
obtained in approximately 5% yield while the 8-isopropyl BODIPY in 42%. Crystal structure of 
8-isopropyl BODIPY (Figure 4-4) revealed similarity to that of the unsubstituted BODIPY, 
where the boron atom exhibited a slight shift from the mean plane of the BODIPY backbone. 
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Figure 4-4 Crystal Structure of isopropyl BODIPY. 
In an attempt to synthesize the ribosyl8-isopropyl dipyrromethane, unforeseen low yields 
were obtained. When the same glycosylation reaction was performed on glucose and galactose, 
anomerically pure products were isolated in high yields, however, the D-ribose gave rise to a 
racemic mixture of a-and f3-anomers. Furthermore, separations of these isomers were very 
difficult by column chromatography. Therefore, with greater difficulty in isolating pure products 
coupled with the relatively lower yields made this process as not a viable strategy for 
oligonucleotide labeling. 
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4.6 BODIPY Phosphoramidite 
After many failed attempts to attach various dipyrromethane derivatives to both ribose 
and deoxyribose, attention was shifted towards the introduction of a hydroxyl function to the 
meso position of BODIPY through a linker. These BODIPY analogues are relatively easy to 
prepare and can be readily transformed into corresponding phosphoramidites. Bromohexanoyl 
chloride 115 was allowed to react with 2,4-dimethyl pyrrole 116 to obtain 8-bromopentyl 
BODIPY 117. Subsequent exchange with potassium acetate and deprotection reveal the primary 
alcohol that would function as the site for phosphitylation. Treatment of the primary alcohol 119 
90 
· _ with N,N-diisopropyl phosphochloridite resulted in a BODIPY building block 120 that was 
compatible for solid phase synthesis (Scheme 4-6). 
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Scheme 4-6: Reagents and conditions: i) CH2Ch; ii) KOAc, DMF; iii) THF:MeOH (2:8 v/v), LiOH, H20; 
iv) (i-Pr)2NEt, THF. 
Initial attempts to incorporate BODIPY into a homo T10 at the 5'-end were carried out on 
a 1.0 ~mol scale using standard DNA synthesis cycle conditions (Appendix A4) with ePG from 
Glen Research (48 ~mollg, 500 A). However, addition of the BODIPY at the 5'-end was 
incubated for 2 min instead of 20 sec. Upon cleavage from the solid support by overnight 
treatment with ammonium hydroxide at 550 C, the products were lyophilized and analyzed by 
anion exchange chromatography. As can be seen from Figure 4-5, use of a 30 mM BODIPY 
phosphoramidite resulted in incomplete coupling reaction (21 %). Figure 4-5 represents an 
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· _ overlay of two spectra in which the retention profile measured using the absorbance at 260 nm 
detects the oligonucleotide and its respective truncated sequences while a second profile at 490 
run detects any BODIPY labeled compounds. A signal detected at approximately 3.30 minutes 
on both profiles indicates the T 10 that is labeled with the BODIPY fluorophore. 
WVL:260 nm 
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Figure 4-5 Overlay of BODIPY-TlO at 490 run (top) and 260 nm (bottom). 
Table 4-2 Integrated peak areas of individual signals corresponding to products and truncated sequences. 
Peak 1 2 3 4 5 6 7 8 9 10 
The coupling yield of the fluorophore could be improved by preparing the solution at 
100 mM. However, a subtle change in fluorescence of the BODIPY fluorophore was noticed 
after exposing it wo many harsh chemicals. Most notably, the treatment with concentrated 
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.. ammonium hydroxide at 55°C for 16 h to cleave the oligonucleotides from the solid support may 
have caused some form of degradation of the fluorophore. The drop in fluorescence and the 
appearance of a brownish-yellow color indicates that the BODIPY core has somehow been 
compromised. In such basic conditions, the most likely scenario is the exchange of the fluorine 
atoms with hydroxides (Figure 4-6). The ammonium hydroxide treatment participates in other 
functions besides cleaving the oligonucleotide. In a heterosequence, protecting groups are found 
on all the phosphate backbone and all nucleobases except thymidine. These protecting groups are 
designed to be base-labile such that during the ammonolysis process, they would be deprotected 
as well. Therefore, an alternative method is required to cleave the oligonucleotide from the solid 
support while keeping the BODIPY fluorophore intact or this methodology would not be a 
viable. 
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Figure 4-6 Exchange of hydroxides with fluorines during ammonium hydroxide treatment. 
4.7 Methoxy BODIPY 
In order to increase the stability of the BODIPY fluorophore under basic conditions, 
derivatives were prepared. There was literature precedence on enhanced BODIPY core stability 
when the fluorines were exchanged with various alkoxy functionalities. Furthermore, these new 
BODIPY cores displayed minimal loss of fluorescence. Substitution of the fluorines on BODIPY 
with methoxy appeared to be straightforward and relatively high yielding.97 Therefore the 
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". methoxy-BODIPY derivative 121 was synthesized in the presence of a Lewis acid such as AICb 
in methanol (Scheme 4-7). 
117 121 
Scheme 4-7: Reagents and conditions: i) AICh, MeOH, CH2Ch 
It can be seen from Figure 4-7 that both the difluoro- and dimethoxy-BODIPY have very 
similar absorbance and emission profiles, with a 2 nm red-shift for dimethoxy-BODIPY in both 
absorption and emission spectra. Furthermore, the fluorescent quantum yields of both 
compounds in methanol were determined using fluorescein as the reference (<I>f = 0.95). The 
fluorine BODIPY has a slightly higher fluorescent quantum yield (0.98 versus 0.91). When the 
fluorine BODIPY and methoxy-BODIPYs were incubated in ammonium hydroxide at 55°C to 
mimic deprotection conditions of oligonucleotides, surprisingly, the methoxy-BODIPY was far 
inferior to the difluoro-BODIPY with respect to stability in basic conditions. In fact, the 
methoxy-BODIPY lost the majority of its fluorescence only after 10 min at room temperature. 
Conversely, the original difluoro-BODIPY was stable for at least 1 hr under the same conditions. 
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Figure 4-7 Absorption and emission profile of Difluoro- and Dimethoxy-BODIPY. 
Table 4-3 Calculated Quantum yields and Molar extinction coefficient. 
Compound Max Absorbance 
JL~ax (nm) 
Max Emission 
JL:x (nm) 
Molar extinction 
coefficient e 
·cm-1 
Quantum Yield 
4lr (CH30H) 
Dimethoxy- 497 504 54400 0.91 
4.8 Ultramild Phosphoramidites and Q-linker 
In order to circumvent the hydrolysis of the BODIPY core, "ultramild" phosphoramidite 
building blocks (Figure 4-8) and the "Q-linker" solid support1l6 were used. Both the ultramild 
phosphoramidite building blocks and the Q-linkers are commercially available from Glen 
Research. The main advantage with ultramild phosphoramdites is based on faster nucleobase 
deprotection which requires ammonium hydroxide incubation of 20 min at room temperature 
instead of the standard 16 h at 550 C. Similarly, Q-linkers are often used in conjunction with 
ultramild phosphoramidites due to faster cleavage of the oligonucleotide from the solid support. 
95 
Figure 4-8 Ultramild phosphoramidites. 
4.9 BODIPY -labeled T 10 and ISIS 5132 
Using a 100 mM solution of BODIPY in dry acetonitrile, BODIPY-T lO was synthesized 
using standard DNA synthesis cycle (Appendix A4). After the products were incubated with 
ammonium hydroxide for 20 min, the final products were analyzed by anion exchange HPLC 
and mass spectrometry (Table 4-4). As can be seen from Figure 4-9, the full length BODIPY-T lO 
was obtained in approximately 91 % yield, which corresponds to an average step-wise coupling 
yield of 99.1 0/0. The HPLC spectrum at 490 nm shows a major peak which represents the 
BODIPY -T 10, however, a small signal to the left of the major peak represents possible labeling 
of truncated sequences. These results show promise to potentially labeling heterosequences. 
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Figure 4-9 HPLC Profile BODIPY-T IO at 260 run (above) and 490 nm (below). 
Using the ultramild phosphoramidite and Q-linker solid supports, the ISIS 5132, a DNA 
20-mer (5'-TCC CGC CTG TGA CAT GCA TT-3') that has been proposed as a candidate in 
cancer therapy,117 was synthesized. The BODIPY fluorophore was incorporated at the 5'- of the 
sequence and analyzed and characterized by anion exchange HPLC (Figure 4-10). 
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Figure 4-10 HPLC Profile BODIPY-ISIS 5132 at 260 run (above) and 490 nm (below). 
Table 4-4 Electrospray mass analysis of BODIPY labeled oligonucleotides. 
BODIPY -ISIS 5132 6438.90 6437.19 
The step-wise coupling efficiency was 99.3%, with an overall yield of 86.7%. Similar to 
the BODIPY -T 10, the HPLC profile at 490 run demonstrates the purity of the oligonucleotide 
sequence by having only one signal at approximately 5.2 min. Furthermore, since there was only 
one signal that was detected at 490 nm, this would be indicative of the BODIPY fluorophore 
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· _ remaining intact during ammonium hydroxide treatment. If any degradation were to occur, a 
second signal should be observed. 
4.10 Conclusion 
BODIPY dyes are well established as versatile fluorophores for labeling of various 
biomolecules. In this respect, BODIPY phosphoramidite derivatives were made such that 
incorporation of these fluorophores may be possible by solid phase DNA synthesis. Although 
there exists other fluorescently derived phosphoramidites such as fluorescein, BODIPY dyes 
have chemical and spectral characteristics that are often superior. Furthermore, these BODIPY 
phosphoramidite analogs were analyzed for their compatibility and stability with regards to 
oligonucleotide deprotection conditions. BODIPY labeled TlO and a hetero sequence ISIS 5132 
were synthesized in high yields and purity. Coupling reactions of greater than 99% and no 
degradation of the BODIPY labeled oligonucleotides were observed. Therefore, the high 
coupling efficiency of the BODIPY phosphoramidite building blocks demonstrated that this may 
be a possible alternative route to labeling oligonucleotide directly. 
Future perspectives of this methodology show great promIse as these BODIPY 
phosphoramidites may be further derivatized to shift emission wavelengths that would 
encompass unique fluorescent colors. Bright green dyes are commonly found, however, more 
uncommon emissions such as violet or red may be a potential goal for the next generation of 
BODIPYphosphoramidites. 
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Chapter 5 - Experimental 
5.1 Spectroscopy 
Broker Avance 300 and 600 Digital NMR spectrometers with a 14.1 and 7.05 Tesla 
Ultrashield magnet, respectively, were used to obtain IH, l3C, 31 p, lIB, and 19F NMR spectrums. 
IH NMR were measured at 300 or 600 MHz, l3C at 75 MHz or 151 MHz, 31p at 121 MHz, lIB at 
96 MHz or 193MHz, and 19F at 282 MHz. Chemical shifts and coupling constants (J values) 
were given in ppm (8) and Hz, respectively. The following deuterated solvents from CIDIN 
isotopes Inc. were used for preparation of NMR samples: dimethyl-d6 sulfoxide + 0.05% 
tetramethylsilane internal standard (99.9 atom % D), chloroform-d (99.9 atom % D), and 
deuterium oxide (99.9 atom % D). Low and high resolution mass spectra were obtained with 
Kratos Concept 1 S high resolution mass spectrometer using electron impact or fast atom 
bombardment sources interfaced with DART 32 bit acquisition system through a Sun 
Sparcstation 10 and Mach 3 software. Bruker HCT Proteineer with electrospray may be 
interfaced with an Agilent 1100 series LC system with built-in auto-sampler and diode array 
detector were used for LC-MS. Lastly, Bruker Autoflex TOF/TOF spectrometer was used for 
MALDI analysis. UV/Vis spectrums were obtained using a Thermospectronic/Unicam UVNis 
spectrometer configured to the Vision32 software. Fluorimetric data were gathered using 
QuantaMaster model QM-2001-4 cuvette-based L-format scanning spectrofluorometer from 
Photon Technology International (PTI) interfaced with FeliX32 software. 
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· -5.2 Chromatography 
Partisil K6F silica gel 60A and SiliaPlate TLC glassback 60A plates were used for TLC. 
EMD silica gel >230 mesh ASTM (O.063mm) was used for short-column chromatography. EMD 
Silica Gel 60A (0.04-0.63 mm) was used for flash-column chromatography. Reverse phase 
HPLC was carried out using a Dionex ICS 3000 System using Hibar RT 250-4 RP-C18 
LiChrospher 100 column (5 f.Lm, 4.6x150 mm) in HPLC grade acetonitrile from EMD, and 0.1 M 
triethylammonium acetate buffer (pH 7). Anion exchange HPLC was performed using BioLC 
DNApac PA-100 (4x250 mm) from Dionex in water, 1.0 MNaCI, and 0.25 M Tris Buffer (pH 
8). Chrome Ie on Client version 6.7 SP3 Build 1884 was interfaced with the HPLC. 
5.2.1 HPLC Elution Program 
Reverse phase HPLC Multi-Step Gradient Programme I 
o 
20 
o 
70 
Anion exchange HPLC Multi-Step Gradient Programme II 
o 
25 
80 
80 
10 
10 
100 
30 
10 
10 
5 
1 
5 
5 
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· -5.3 DNA Synthesizer 
All solid phase syntheses of RNA and DNA sequences were performed using Applied 
Biosystem's ABI 3400 DNA synthesizer. DNA synthesis grade acetonitrile and Deblocking 
solution were purchased from Fisher Scientific, Capping solutions from Novabiochem, 
Oxidation solution from Em Science, and dichloromethane from lTBaker. Solid support resins 
were obtained from Proligo Reagents, Glen Research and 3-Prime. Ultramild phosphoramidite 
building blocks and fluorescein phosphoramidite were purchased from Glen Research. 
5.4 Solvents and Chemicals 
Benzene and diethyl ether were dried by heating under reflux for 4 h over sodium and 
then distilled. Diethylamine, diisopropylamine, pyrrolidine, piperidine, and pyridine were dried 
by heating under reflux for 4 h over calcium hydride and then distilled. CH2Ch, THF, 
ac~tonitrile were dried using the Pure Solv system from Innovative Technology Inc. All other 
reagents were bought from Sigma-Aldrich or VWR Canlab without further purification prior to 
use. 
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.1 
· -5.5 Preparation of Compounds 
3' ,5' -0-(1,1,3,3-Tetraisopropyldisiloxyl) uridine 79 
o 
I NH 
ib" I}~ OH 
Uridine 78 (10.00 g, 40.95 mmol) was dried at 60°C in vacuo for 5 h and then suspended 
in pyridine (50 mL) followed by addition of 1,3-dichloro-l,I,3,3-tetraisopropyldisoloxane (14.6 
mL, 45.76 mmol) at O°C (ice-water bath). After 5 h, water (10 mL) was added and after a further 
period of 10 min, the reaction mixture was concentrated under reduced pressure. The residue was 
dissolved in dichloromethane (150 mL) and washed with saturated aqueous sodium bicarbonate 
(150 mL). The layers were separated and the aqueous layer back extracted with dichloromethane 
(3 x30 mL). The combined organic layers were dried (MgS04) and concentrated under reduced 
pressure. The residue was purified by short column chromatography. Fractions were eluted with 
dichloromethane-methanol (98:2, v/v). The combined fractions were evaporated under reduced 
pressure to give the title compound as a colourless foam (19.33 g, 97%). 
bH[(CD3)2S0]: 11.37 (1 H, s, NH, ex), 7.7 (1 H, d, J = 7.9 Hz, H-6), 5.60 (1 H, d, J = 4.4 Hz, H-
5),5.56 (1 H, d, J= 4.5 Hz, H-l'), 4.07 - 4.21 (3 H, m, H-2', H-3', H-4'), 3.91 - 4.05 (2 H, m, 
H-5', H-5"), 0.95 - 1.10 (28 H, m, Si-CH(CH3». 
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· Dc[(CD3)2S0]: 163.9 (C=O, C4), 150.6 (C=O, C6), 140.3 (CH, C6), 124.4 (CH), 101.4 (CH, C5), 
91.0 (C-1'), 81.4 (C-4'), 74.0 (C-2'), 69.3 (C-3'), 60.7 (C-5'), 17.3 - 17.9 (CH3), 12.3 - 13.3 
(CH). 
Rf : 0.55 (Dichloromethane-MethanoI95:5, v/v). 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-3' ,5' -0-(I,I,3,3-tetraisopropyldisiloxyl) 
uridine 122 
3',5'-O-(1,1,3,3-Tetraisopropyldisiloxyl) uridine 79 (10.00 g, 20.55 mmol) and 1-(4-
chlorophenyl)-4-ethoxy-1,2,5,6-tetrahydropyridine76 (11.02 g, 46.24 mmol) were co-evaporated 
with dry toluene (2x20 mL). The residue was dissolved in dry dichloromethane (100 mL) and 
trifluoroacetic acid (4.00 mL, 53.43 mmol) was added. The reaction was allowed to proceed for 
6 h at room temperature. Triethylamine (7.8 mL, 55.5 mmol) was added and after 5 min, the 
reaction mixture was washed with saturated sodium bicarbonate (150 mL). The organic layers 
were dried (MgS04) and concentrated under reduced pressure. The mixture was purified by 
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, I 
1 
- I 
.. column chromatography. The product was eluted with dichloromethane-methanol (98:2, v/v) and 
the appropriate fractions were concentrated under reduced pressure to give the title compound as 
a colourless foam (13.75 g, 92%). 
8H[(CD3)2S0]: 11.39 (1 H, s, NH), 7.95 (1 H, d, J = 7.8 Hz, H-6), 7.17 (2H, d, J = 4.9 Hz, Ar-
H), 6.91(2H, d, J = 4.8 Hz, Ar-H), 5.62 (1 H, d, J = 4.4 Hz, H-5), 5.56 (1 H, d, J = 4.5 Hz, H-l '), 
4.01 - 4.55 (3 H, m, H-2', H-3', H-4'), 3.82 - 3.96 (2 H, m, H-5', H-5"), 0.95 - 1.10 (28 H, m, 
Si-CH(CH3)). 
8c[(CD3)2S0]: 163.6 (C=O, C4), 150.6 (C=O, C6), 141.2 (CH, C6), 129.3 (CH, Ar-C), 122.3 
(CH), 117.4 (CH, Ar-C), 101.8 (CH, C5), 90.3 (C-l '), 81.6 (C-4'), 72.6 (C-2'), 69.0 (C-3'), 60.6 
(C-5'), 17.3 - 17.9 (CH3), 12.3 - 13.3 (CH). 
Rf : 0.68 (Dichloromethane-MethanoI95:5, v/v) . 
2' -0- [1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl] uridine 80 
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2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-3' ,5' -0-(1,1 ,3,3-tetraisopropyl 
disiloxyl) uri dine 122 (13.75 g, 18.98 mmol) was dissolved in acetonitrile (50 mL) followed by 
addition of tetraethylammonium fluoride solution (41.50 mL, 1.0 M, pH 8.0). After 30 min, the 
products were concentrated under reduced pressure and partitioned between dichloromethane 
(250 mL) and saturated sodium bicarbonate (150 mL). The aqueous layer was back-extracted 
with dichloromethane (3x50 mL). The combined organic layers were dried (MgS04) and 
concentrated under reduced pressure. The residue was purified by column chromatography. The 
product was eluted with dichloromethane-methanol (96:4, v/v) and the appropriate fractions were 
concentrated under reduced pressure to give the title compound as a colourless foam (8.59 g, 
94%). 
DH[(CD3)2S0]: 11.36 (1 H, s, NH), 8.01 (1 H, d, J = 7.8 Hz, H-6), 7.17 (2 H, d, J = 4.9 Hz, Ar-
H), 6.91 (2 H, d, J = 4.8 Hz, Ar-H), 6.01 (1 H, d, J = 4.4 Hz, H-1 '), 5.75(1 H, d, J = 4.5 Hz, H-
5),4.36 (1 H, m, H-2'), 4.01 (1 H, m, H-3'), 3.92 (1 H, m, H-4'), 3.12 - 3.3 (4 H, m, CH2), 2.81 
- 3.12 (2 H, m, H-5', H-5"). 
Dc[(CD3)2S0]: 163.4 (C=O, C4), 151.3 (C=O, C6), 141.3 (CH, C6), 129.1 (CH, Ar-C), 117.6 
(CH, Ar-C), 103.1 (CH, C5), 87.0 (C-l '),86.0 (C-4'), 72.6 (C-2'), 72.1 (C-3'), 62.1 (C-5'). 
Rr: 0.39 (Dichloromethane-Methanol 95:5, v/v) 
106 
-2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5'-0-dimethoxytrityl uridine 81 
OMe 
2'-O-[I-(4-Chlorophenyl)-4-ethoxypiperidin-4-yl] uridine 80 (10.00 g, 20.81 mmol) was 
co-evaporated with dry pyridine (20 mL). The residue was redissolved in dry pyridine (60 mL) 
followed by addition of dimethoxytrityl chloride (7.40 g, 21.85 mmol). After 1 h, methanol (10 
mL) was added. After 5 min, the products were partitioned between dichloromethane (80 mL) 
and saturated sodium bicarbonate (80 mL). The aqueous layer was back-extracted with 
dichloromethane (2x30 mL). The combined organic layers were dried (MgS04) and concentrated 
under reduced pressure. The residue was purified by column chromatography. The product was 
eluted with dichloromethane-methanol (96:3, v/v) and the appropriate fractions were 
concentrated under reduced pressure to give the title compound as a yellow foam (15.51 g,95%). 
()H[(CD3hSO]: 11.42 (1 H, s, NH), 7.71 (1 H, d, J = 7.8 Hz, H-6), 6.85 - 7.45 (17 H, m, DMTr 
Ar-H and Cpep Ar-H), 6.02 (1 H, d, J = 4.4 Hz, H-1 '),5.42(1 H, d, J = 4.5 Hz, H-5), 4.59 (1 H, 
m, H-2'), 4.15 (1 H, m, H-3'), 4.04 (1 H, m, H-4'), 2.81- 3.12 (2 H, m, H-5', H-5"). 
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"- Dc[(CD3)2S0]: 163.2 (C=O, C4), 151.1 (C=O, C6), 140.9 (CH, C6), 129.1 (CH, Ar-C), 117.6 
(CH, Ar-C), 102.8 (CH, C5), 86.1 (C-l '),84.6 (C-4'), 72.2 (C-2'), 71.3 (C-3'), 64.2 (C-5'). 
Rr: 0.65 (Dichloromethane-Methanol 95:5, v/v). 
2-Cyanoethyl-phosphodichloridite 123 
3-Hydroxypropionitrile (54.0 mL, 0.79 mol) and 1,1,1,3,3,3-hexamethyldisilazane (84.0 
mL, 0.40 mol) were mixed and heated at 135°C. After 2 h, the products were cooled to room 
temperature. Dry acetonitrile (500 mL) was added, and this solution was added dropwise to a 
solution of phosphorus trichloride (75.0 mL, 0.86 mol) in acetonitrile (800 mL) at -40°C over a 
period of 2 h. After the addition was complete, the reaction mixture was allowed to warm up to 
room temperature over a period of 2 h. The products were then concentrated under reduced 
. . , 
pressure. The viscous liquid was then distilled under vacuum (90°CIl mmHg) to give the title 
compound as a colourless liquid (67.1 g, 98%) 
(2-Cyanoethyl) N,N-diethyl phosphochloridite 71 
Dry diethylamine (30.30 mL, 0.29 mol) in dry diethyl ether (90 mL) was added dropwise 
to a solution of 2-cyanoethyl phosphodichloridite 123 (25.0 g, 0.145 mol) in dry diethyl ether 
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-(380 mL) at -20°C over a period of 2 h. After the addition was complete, the reaction mixture 
was allowed to warm to room temperature and stirring was continued for another 20 h. The 
products were filtered by cannular filtration and the filtrate was concentrated under reduced 
pressure. The viscous liquid was then distilled under vacuum (140oC/1mmHg) to give the title 
compound as a colourless liquid (28.6 g, 95%). 
(2-Cyanoethyl) N,N-diisopropyl phospbochloridite 70 
Dry diisopropylamine (40.75 mL, 0.29 mol) in dry diethyl ether (80 mL) was added 
dropwise to a solution of 2-cyanoethyl phosphodichloridite 123 (25.0 g, 0.145 mol) in dry 
diethyl ether (350 mL) at -20°C over a period of 2 h. After the addition was complete, the 
reaction mixture was allowed to warm to room temperature and stirring was continued for 
another 20 h. The products were filtered by cannular filtration and the filtrate was concentrated 
under reduced pressure. The viscous liquid was then distilled under vacuum (140°CllmmHg) to 
give the title compound as a colourless liquid (31.4 g, 91 %). 
* D20 Capillary 109 
· -(2-Cyanoethyl) piperidino phosphochloridite 72 
Dry piperidine (11.5 mL, 0.12 mol) in dry diethyl ether (50 mL) was added dropwise to a 
solution of 2-cyanoethyl phosphodichloridite 123 (10.0 g, 58.0 mmol) in dry diethyl ether (150 
mL) at -20°C over a period of 2 h. After the addition was complete, the reaction mixture was 
allowed to warm to room temperature and stirring was continued for another 20 h. The products 
were filtered by cannular filtration and the filtrate was concentrated under reduced pressure. The 
viscous liquid was then distilled under vacuum (140°C/1mmHg) to give the title compound as a 
colourless liquid (11.8 g, 92%). 
(2-Cyanoethyl) pyrrolidino phosphochloridite 73 
Dry pyrrolidine (9.52 mL, 0.12 mol) in dry diethyl ether (50 mL) was added dropwise to 
a solution of 2-cyanoethyl phosphodichloridite 123 (10.0 g, 58.0 mmol) in dry diethyl ether (150 
mL) at -20°C over a period of 2 h. After the addition was complete, the reaction mixture was 
allowed to warm to room temperature and stirring was continued for another 20 h. The products 
were filtered by cannular filtration and the filtrate was concentrated under reduced pressure. The 
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-viscous liquid was then distilled under vacuum (140°C/lmmHg) to give the title compound as a 
colourless liquid (10.3 g 86%). 
2' -0- [1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yIJ-5' -O-dimethoxytrityl uridine 3' -0-(2-
cyanoethyl) N ,N-diethylphosphoramidite 65 
OMe 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -O-dimethoxytrityl uridine 82 (2.00 
g,2.55 mmol) was co-evaporated with dry toluene (10 mL) and was redissolved in dry 
tetrahydrofuran (10 mL). N,N-Diisopropylethylamine (1.2 mL, 7.28 mmol) and 2-cyanoethyl 
N,N-diethyl phosphochloridite 71 (0.84 g, 4.05 mmol) were added. The reaction was allowed to 
proceed for 30 min and the products were concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel. The product was eluted with hexane-acetone-
triethylamine (59:39:2, v/v) and the appropriate fractions were concentrated under reduced 
pressure to give the title compound as a colourless foam (2.1 g, 86%) 
* DzO Capillary 111 
-8H[(CDCb]: 7.75 (1 H, d, J= 6.1 Hz, H-6), 7.14 -7.49 (17 H, m, DMTr Ar-H and Cpep Ar-H), 
6.l2 (1 H, d, J = 4.4 Hz, H-l '), 5.55(1 H, d, J = 4.5 Hz, H-5), 4.75 (1 H, m, H-2'), 4.62 (1 H, m, 
H-3 '),4.23 (1 H, m, H-4'), 3.25 - 3.54 (2 H, m, H-5', H-5"). 
8p[CDCb]: 150.9 and 149.9 
Rf: 0.57 (Hexane-Acetone-Triethylamine 59:39:2, v/v). 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -O-dimethoxytrityl uridine 3' -0-(2-
cyanoethyl) N,N-diisopropylphosphoramidite 64 
OMe 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-y I] -5' -O-dimethoxytrity I uri dine 82 (2.00 
g, 2.55 mmol) was co-evaporated with dry toluene (10 mL) and was redissolved in 
tetrahydrofuran (10 mL). N,N-Diisopropylethylamine (1.2 mL, 7.28 mmol) and 2-cyanoethyl 
N,N-diisopropyl phosphochloridite 70 (0.96 g, 4.05 mmol) were added. The reaction was 
allowed to proceed for 30 min and the products were concentrated under reduced pressure. The 
residue was purified by column chromatography. The product was eluted with hexane-acetone-
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· -triethylamine (59:39:2, v/v) and the appropriate fractions were concentrated under reduced 
pressure to give the title compound as a colourless foam (2.11 g, 84%). 
bH[CDCb]: 7.69 (1 H, d, J = 7.2 Hz, H-6), 7.17 - 7.53 (17H, m, DMTr Ar-H and Cpep Ar-H), 
6.06 (1 H, d, J= 4.4 Hz, H-l '),5.45(1 H, d, J= 4.5 Hz, H-5), 4.77 (1 H, m, H-2'), 4.22 (1 H, m, 
H-3 '),4.73 (1 H, m, H-4'), 3.25 - 3.54 (2 H, m, H-5', H-5"). 
bp[CDCb]: 151.5 and 149.4 
Rf: 0.57 (Hexane-Acetone-Triethylamine 59:39:2, v/v). 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]- 5' -O-dimethoxytrityl uridine 3'-0-(2-
cyanoethyl) piperidinophosphoramidite 66 
OMe 
(:NH NAo 
MeO 0'd OEt 
_~/O,/ 
-# ~ P 
o 00 
N 6 Q 
CI 
2' -0-[ 1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -O-dimethoxytrityl uridine 82 (0.50 
g, 0.64 mmol) was co-evaporated with dry toluene (10 mL) and was redissolved in 
tetrahydrofuran (10 mL). N,N-Diisopropylethylamine (0.30 mL 1.82 mmol) and 2-cyanoethyl 
piperidino phosphochloridite 72 (0.224 g, 1.016 mmol) were added. The reaction was allowed to 
proceed for 30 min and the products were concentrated under reduced pressure. The residue was 
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· -purified by column chromatography. The product was eluted with hexane-acetone-triethylamine 
(59:39:2, v/v) and the appropriate fractions were concentrated under reduced pressure to give the 
title compound as a colourless foam (0.46 g, 74%) 
bH[CDCh]: 7.69 (1 H, d, J= 7.2 Hz, H-6), 7.17 -7.53 (17 H, m, DMTr Ar-H and Cpep Ar-H), 
6.06 (1 H, d, J = 4.4 Hz, H-l '), 5.45(1 H, d, J = 4.5 Hz, H-5), 4.77 (1 H, m, H-2'), 4.22 (1 H, m, 
H-3'), 4.13 (1 H, m, H-4'), 3.25 - 3.54 (2 H, m, H-5', H-5"). 
bp[D20*]: 145.2 and 144.7 
Rf: 0.60 (Hexane-Acetone-Triethylamine 59:39:2, v/v). 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -O-dimethoxytrityl uridine 3' -0-(2-
cyanoethyl) pyrrolidinophosphoramidite 67 
OMe 
2' -0-[1-( 4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5' -O-dimethoxytrityl uri dine 82 (0.50 
g, 0.64 mmol) was co-evaporated with dry toluene (10 mL) and was redissolved in 
tetrahydrofuran (10 mL). N,N-Diisopropylethylamine (0.3 mL 1.82 mmol) and 2-cyanoethyl 
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· -pyrrolidino phosphochloridite 73 (0.20 g, 1.016 mmol) were added. The reaction was allowed to 
proceed for 3 h and the products were concentrated under reduced pressure. The residue was 
purified by column chromatography. The product was eluted with hexane-acetone-triethylamine 
(59:39:2, v/v) and the appropriate fractions were concentrated under reduced pressure to give the 
title compound as a colourless foam (0.41 g, 66%). 
oH[CDCh]: 7.70 (1 H, d, J = 7.2 Hz, H-6), 7.18 - 7.50 (17 H, m, DMTr Ar-H and Cpep Ar-H), 
6.07 (1 H, d, J = 4.4 Hz, H-l '), 5.43(1 H, d, J = 4.5 Hz, H-5), 4.78 (1 H, m, H-2'), 4.21 (1 H, m, 
H-3'), 4.18 (l H, m, H-4'), 3.23 - 3.55 (2 H, m, H-5', H-5"). 
op[D20*]: 145.8 and 145.2 
Rf : 0.57 (Hexane-Acetone-Triethylamine 59:39:2, v/v). 
2',3' -O-Diacetyl-5' -O-dimethoxytrityl uridine 124 
. 1 
Uridine 78 (3.00 g, 12.3 mmol) was dried at 70°C in vacuo for 3 h and then suspended in 
pyridine (30 mL) followed by addition of dimethoxytrityl chloride (4.58 g, 13.53 mmol). The 
reaction was allowed to proceed for 2 h before partitioning between dichloromethane (50 mL) 
and saturated sodium bicarbonate (50 mL). The aqueous layer was back-extracted with 
dichloromethane (2x30 mL). The combined organic layers were dried (MgS04) and concentrated 
under reduced pressure. The crude material was redissolved in dry pyridine (20 mL) followed by 
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· -addition of acetic anhydride (2.5 mL, 27.1 mmol). After 3 h, the reaction solution was partitioned 
between dichloromethane (50 mL) and saturated sodium bicarbonate (50 mL). The aqueous layer 
was back-extracted with dichloromethane (2x30 mL) and the combined organic layers were 
dried (MgS04) and evaporated under reduced pressure. The crude oil was purified by column 
chromatography and the desired material was eluted with dichloromethane-methanol (96:3, v/v) 
and the appropriate fractions were concentrated under reduced pressure to give the title 
compound as a yellow foam (6.52 g, 84%). 
DH[(CD3hSO]: 11.46 (1 H, s, NH), 7.69 (1 H, d, J = 7.8 Hz, H-6), 6.82 - 7.42 (13 H, m, DMTr 
Ar-H), 5.92 (1 H, d, J = 4.4 Hz, H-l '), 5.51(1 H, d, J = 4.5 Hz, H-5), 4.43 (1 H, m, H-2'), 4.19 (1 
H, m, H-3 '), 3.37 (1 H, m, H-4'), 3.21 - 3.31 (2 H, m, H-5', H-5"), 2.08 (3H, s, OAc), 2.06 (3H, 
s,OAc). 
Rf: 0.65 (Dichloromethane-MethanoI95:5, v/v). 
2' ,3' -0-Diacetyl uridine 68 
2' ,3' -O-Diacetyl-5' -O-dimethoxytrityl uri dine 124 (5.00 g, 7.93 mmol) was dissolved in 
dry dichloromethane (50 mL) and to this solution was added pyrrole (5.13 mL, 39.64 mmol) and 
dichloroacetic acid (5.06 mL, 39.64 mmol). After 10 min, the solution was partitioned between 
dichloromethane (80 mL) and saturated sodium bicarbonate (70 mL). The aqueous layer was 
back extracted with dichloromethane (2x30 mL). The combined organic layers were dried 
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· -(MgS04) and evaporated under reduced pressure. The residue was purified by column 
chromatography and the products eluted with dichlromethane-methanol (95:5, v/v). The 
appropriate fractions were collected and evaporated under reduced pressure to give the title 
compound as a light brown foam (2.01 g, 77%). 
oH[(CD3)2S0]: 11.41 (1 H, s, NH), 7.90 (1 H, d, J = 7.8 Hz, H-6), 6.02 (1 H, d, J = 4.4 Hz, H-
1 '), 5.71(1 H, d, J = 4.5 Hz, H-5), 5.42 (1 H, m, H-2'), 5.34 (1 H, m, H-3'), 4.13 (1 H, m, H-4'), 
3.55 - 3.72 (2 H, m, H-5', H-5"), 2.10 (3H, s, OAc), 2.03 (3H, s, OAc). 
oc[(CD3)2S0]: 170.0 (C=O, OAc), 169.8 (C=O, OAc), 163.4 (C=O, C4), 151.0 (C=O, C6), 140.8 
(CH, C6), 103.1 (CH, C5), 85.9 (C-l '), 83.6 (C-4'), 72.8 (C-2'), 71.5 (C-3'), 61.2 (C-5'), 20.9 
(CH3, OAc), 20.7 (CH3, OAc). 
Rf : 0.37 (Dichloromethane-Methanol 95:5, v/v). 
O,O'-Diethyl S-phenylphosphorothioate 77 
EtO", ~O P~ 
EtO/ "'SPh 
Diethyl phosphite 75 (0.50 g, 3.6 mmol) was diluted with dry pyridine (10 mL) followed 
by the addition of phenylsulfanyl-pyrrolidine-2,5-dione1l8, 119 (1.50 g, 7.2 mmol). After 16 h of 
stirring at room temperature, the reaction mixture was evaporated under reduced pressure to 
remove excess pyridine. The crude material was redissolved in ethyl acetate (2 mL) and 
precipitated in cold ether (20 mL). The products were further purified by column 
chromatography and eluted with hexane-ethyl acetate (1: 1 v/v) to obtain the title compound (0.70 
g,85%). 
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"bH[CDCh]: 7.25 - 7.61 (5 H, m, Ar-H), 4.16 (6 H, q, J = 6.1 Hz, CH3), 1.2 (3.9 H, t, J = 6.1 Hz, 
bp[CDCh]: 21.8 
5'-D-(2,7-Dimethyl)pixyl thymidine 84 
Thymidine 83 (3.00 g, 12.4 mmol) was co-evaporated with dry pyridine (15 mL). The 
residue was redissolved in dry pyridine (15 mL) followed by addition of dimethylpixyl chloride 
(4.57 g, 14.3 mmol). After 1.5 h, methanol (5 mL) was added. After 5 min, the products were 
partitioned between dichloromethane (30 mL) and saturated sodium bicarbonate (30 mL). The 
aqueous layer was back-extracted with dichloromethane (2x30 mL). The combined organic 
layers were dried (MgS04) and concentrated under reduced pressure. The residue was purified 
by column chromatography. The product was eluted with dichloromethane-methanol (96:3, v/v) 
and the appropriate fractions were concentrated under reduced pressure to give the title 
compound as a yellow foam (5.56 g, 85%). 
bH[(CD3)2S0]: 11:33 (1 H, s, NH), 7.55 (1 H, s, H-6), 7.02-7.35 (11 H, m, DMPx Ar-H), 6.02 (1 
H, t, J= 8.9 Hz, H-I'), 5.34 (1 H, s, 3'-OH), 4.33 (1 H, m, H-3'), 3.85 (1 H, m, H-4'), 3.02-
3.22 (2 H, m, H-5', H-5"), 2.29 (1 H, m, H-2'), 2.18 (3 H, s, DMPx CH3), 2.13 (3 H, s, DMPx 
Rf: 0.55 (Dichloromethane-MethanoI95:5, v/v). 
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· -5'-0-(2,7-Dimethyl)pixyl thymidine 3'-0-(2-cyanoethyl) diisopropylphosphoramidite 85 
5' -O-Dimethylpixyl thymidine 84 (1.01 g, 1.9 mmol) was co-evaporated with dry toluene 
(10 mL) and was redissolved in tetrahydrofuran (10 mL). N,N-Diisopropylethylamine (0.66 mL, 
3.8 mmol) and 2-cyanoethyl N,N-diisopropyl phosphochloridite 70 (0.72 g, 3.1 mmol) were 
added. The reaction was allowed to proceed for 30 min and the products were concentrated under 
reduced pressure. The residue was purified by column chromatography. The product was eluted 
with hexane-acetone-triethylamine (59:39:2, v/v) and the appropriate fractions were concentrated 
under reduced pressure to give the title compound as a colourless foam (1.10 g, 80%). 
bH[(CDCh]: 11.36 (1 H, s, NH), 7.54 (1 H, s, H-6), 7.01- 7.30 (11 H, m, DMPx Ar-H), 6.23 (1 
H, t, J= 5.9 Hz, H-1'), 4.60 (1 H, m, H-3'), 4.01 (1 H, m, H-4'), 3.04 - 3.25 (2 H, m, H-5', H-
5"),2.78 (1 H, m, H-2'), 2.51 (6 H, s, DMPx CH3). 
bp[CDCh]: 148.1 and 147.1 
Rf: 0.48 (Hexane-Acetone-Triethylamine 59:39:2, v/v). 
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· -2,3,4,6-0-Tetraacetyl D-glucose 94 
OAc 
~ AcO AcO OH 
OAc 
D-Glucose 92 (2.30 g, 12.8 mmol) was dried under vacuo for 3 h at 40°C and was then 
dissolved in dry pyridine (30 mL) followed by addition of acetic anhydride (24.0 mL, 0.256 
mol). After stirring for 16 h at room temperature, the reaction was quenched with addition of 
methanol (10 mL). The solution was concentrated under reduced pressure and was then 
partitioned between dichloromethane (100 mL) and saturated aqueous sodium bicarbonate (80 
mL). The layers were separated and the aqueous layer was back-extracted with dichloromethane 
(2x20 mL). The combined organic layers were dried (MgS04) and concentrated under reduced 
pressure. The residue was redissolved in ethyl acetate (2 mL) and precipitated with cold hexane 
(100 mL) while stirring. The precipitate was collected by filtration to give 1,2,3,4,6-0-
pentaacetyl D-glucose 93 as a white solid. This material was then dissolved in DMF (20 mL), 
followed by addition ofhydrazine acetate (prepared by mixing hydrazine hydrate (0.75 mL) with 
acetic acid (1.43 mL) in dichloromethane (2.0 mL), 15.4 mmol) slowly. After 45 min, the 
products were evaporated under reduced pressure and the residue was redissolved in 
dichloromethane (100 mL) and extracted with saturated aqueous sodium bicarbonate (80 mL). 
The layers were separated and the aqueous layer was back -extracted with dichloromethane (2x20 
mL). The combined organIc layers were dried (MgS04) and concentrated under reduced 
pressure. The material was purified by column chromatography on silica gel. The appropriate 
fractions were eluted with dichloromethane-methanol (97:3, v/v) and the desired products were 
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· -combined and evaporated under reduced pressure to give the title compound as a white foam 
(3.70 g, 83 %). 
8H[CDCh]: 5.51 (1 H, t,J= 9.1 Hz, H-3), 5A5 (1 H, d,J= 3.1 Hz, H-1), 5.19 (1 H, t,J= 9.1 Hz, 
H-2), 5.04 (1 H, t, J = 9.1 Hz, H-4), 4.84 (1 H, dd, J = 6.1 and 9.1 Hz, H-5), 4.26 (1 H, dd, J = 
3.1 and 6.1 Hz, H-6), 4.21 (1 H, dd, J= 3.1 and 6.1 Hz, H-6'), 2.05 (3 H, s, CH3), 2.03 (3 H, s, 
Rf : OA5 (Dichloromethane-Methanol 95:5, v/v). 
2,3,4,6-0-Tetraacetyl-a-D-glucosyl-trichloroacetimidate 95 
2,3,4,6-0-Tetraacetyl D-glucose 94 (3.00 g, 8.61 mmol) was co-evaporated with dry 
toluene (10 mL) and then dissolved in dry dichoromethane (20 mL). The reaction mixture was 
cooled to DOC (ice-water bath) and trichloroacetonitrile (lOA mL, 0.10 mol) and 1,8-
diazabicyc10[5A.0]undec-7-ene (DBU) (0.36 mL, 2A mmol) were added. After 1 h, the reaction 
mixture was washed with saturated aqueous sodium bicarbonate (70 mL). The layers were 
separated and the aqueous layer was back-extracted with dichloromethane (2x20 mL). The 
combined organic layers were dried (MgS04) and concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel. The products were eluted with 
toluene-ethyl acetate (3:1, v/v) and the appropriate fractions were collected and evaporated under 
reduced pressure to give the title compound as a white foam (3 A4 g, 81 %). 
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-bH[CDCh]: 8.69 (1 H, s, NH), 6.55 (1 H, d, J= 3.1 Hz, H-l), 5.56 (1 H, t, J= 9.1 Hz, H-3), 5.18 
(1 H, t, J= 9.1 Hz, H-2), 5.14 (1 H, t, J= 9.1 Hz, H-4), 4.05 - 4.35 (3 H, m, H-5, H-6, H-6'), 
2.07 (3 H, s, CH3), 2.04 (3 H, s, CH3), 2.03 (3 H, s, CH3), 2.01 (3 H, s, CH3). 
Rf: 0.55 (Toluene-Ethyl acetate 1: 1, v/v). 
1- (2,3,4,6-0-Tetraacetyl-p-D-glucosyl)pyrrole 97 
OAc 
ACO~--O n A~O~ __ ) 
OAc N 
H 
2,3,4,6-0-Tetraacetyl-a-D-glucosyl-trichloroacetimidate 95 (l.00 g, 2.0 mmol) and 
pyrrole 96 (2.8 mL, 40.0 mmol) were dissolved in dry dichloromethane (15 mL). The solution 
was cooled to O°C and boron trifluoride diethyl etherate (0.17 mL, 1.3 mmol) was added. After 
30 min, the products were partitioned between dichloromethane (30 mL) and saturated aqueous 
sodium bicarbonate (30 mL). The organic layer was dried (MgS04) and concentrated under 
reduced pressure. The residue was purified by column chromatography on silica gel. The 
appropriate fractions, which were eluted with dichloromethane-methanol (99:1, v/v), were 
combined and concentrated under reduced pressure to give the title compound brown foam (0.68 
g,84%). 
bH[CDCh]: 8.44 (1 H, s, NH), 6.79 (l H, m, H-5), 6.10 - 6.18 (2 H, m, H-3, H-4), 5.32 (1 H, t, J 
= 6.1 Hz, H-3'), 5.20 (l H, t, J= 9.1 Hz, H-4'), 5.18(1 H, t, J = 5.9, H-2'), 4.54 (1 H, d, J = 9.1 
Hz, H-l '), 4.07 - 4.35 (3 H, m, H-5, H-6, H-6'), 2.10 (3 H, s, CH3), 2.07 (3 H, s, CH3), 2.03 (3 
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<-Rf: 0.63 (Dichloromethane-MethanoI95:5, v/v) 
4,4-Difluoro-4-bora-8-phenyl-3a,4a-diaza.;.s-indacene 102 
Pyrrole 96 (1.25 mL, 18 mmol) and BF3·Et20 (2.39 mL, 19.0 mmol) were combined in 
dry dichloromethane (20 mL) and to this solution was added trimethyl orthobenzoate 101 (0.35 
mL, 2.0 mmol) in dry dichloromethane (10 mL) drop-wise at O°C. After refluxing for 2 h, the 
reaction solution was washed with saturated sodium bicarbonate (2x30 mL) and dried (MgS04). 
The solution was evaporated under reduced pressure and purified by column chromatography on 
silica. The products were eluted with dichloromethane and evaporation of the appropriate 
fractions gave the title compound as a dark brown solid (0.20 g, 36%). 
bH[CDCh]: 7.98 (2 H, s, H-3, H-5), 7.51 - 7.69 (5 H, m, Ar-H), 6.91 - 7.03 (2 H, m, H-l, H-7), 
6.51 - 6.61 (2 H, m, H-2, H-6). 
bc[CDCh]: 144.1 (C-3, C-5), 135.2 (Ar-C2, Ar-C6), 133.1 (Ar-C3, Ar-C5), 132.1 (Ar-C4), 130.2 
(C-l, C-7), 118.1 (C-2, C-6). 
bF[CDCh]: 145.2 (q, J = 2.9 Hz) 
Rf: 0.56 (Hexane-Diethyl ether 1: 1, v/v). 
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· -2,2'-Dipyrrothione 104 
s 
a:o 
Pyrrole 96 (12.0 mL, 0.17 mol) in dry diethyl ether (30 mL) was added drop-wise to a 
solution of thiophosgene (6.67 mL, 87.0 mmol) in dry diethyl ether (30 mL) at O°C. After 30 
min, the reaction was quenched by the addition of methanol (20 mL) and was stirred for an 
additional 30 min. The reaction mixture was evaporated under reduced pressure and the dark oil 
was purified by column chromatography. The products were eluted with toluene-
dichloromethane (90: 10 v Iv) and the appropriate fractions were collected and evaporated under 
reduced pressure to give the title compound as purple crystals (3.51 g 25%). 
8H[CDCb]: 9.77 (2 H, s, br, NH), 7.21 - 7.25 (2 H, m, H-1, H-1 '), 7.04 - 7.10 (2 H, m, H-3, H-
3'),6.40 - 6.48 (2 H, m, H-2, H-2'). 
Rf: 0.62 (Dichloromethane). 
2,2'-Dipyrroketone 105 
o 
a:o 
Hydrogen peroxide (14.52 mL, 35% w/v) was added drop-wise to a solution of 2,2'-
dipyrrothione 104 (3.50 g, 20 mmol) and potassium hydroxide (4.40 g, 78.4 mmol) in methanol-
water (95:5 v/v) at O°C. Once the addition was completed, the reaction mixture was refluxed for 
5 min and then cooled to room temperature. Distilled water (175 mL) was added at O°C and the 
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· -reaction was allowed to proceed for 2 h before filtration and the products were isolated as yellow 
needle crystals (1.4, 45%). 
bH[CDCb]: 9.64 (2 H, s, br, NH), 7.14 - 7.22 (2 H, m, H-1, H-1 '), 7.06 - 7.14 (2 H, m, H-3, H-
3'),6.33 - 6.42 (2 H, m, H-2, H-2'). 
Rf : 0.60 (Dichloromethane). 
2,2'-Dipyrromethane 106 
a::o 
2,2' -Dipyrroketone 105 (1.00 g, 6.2 mmol) and sodium borohydride (2.27 g, 62 mmol) 
were dissolved in ethanol-water (20 mL, 95:5 v/v) and refluxed for 3 h. The reaction was then 
quenched with the addition of distilled water (l0 mL). The solvents were evaporated under 
reduced pressure. The residue was then redissolved in diethyl ether (30 mL) and partitioned with 
saturated sodium bicarbonate (20 mL) and the organic layer was collected and dried (MgS04). 
The solution was evaporated under reduced pressure and the residue was purified by column 
chromatography. The products were eluted with dichloromethane and combined to be evaporated 
under reduced pressure to obtain the title compound as a colorless solid (0.52 g, 57%). 
bH[CDCI3]: 7.84 (2 H, s, br, NH), 6.64 - 6.72 (2 H, m, H-1, H-1 '), 6.14 - 6.22 (2 H, m, H-3, H-
3'),6.04 - 6.09 (2 H, m, H-2, H-2'), 3.99 (2 H, s, CH2). 
Rf : 0.75 (Dichloromethane). 
125 
-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene 107 
~ N'B~NJ
" , F F 
2,2' -Dipyrromethane 106 (50.0 mg, 0.342 mmol) was azeotroped with dry toluene (3 
mL) and was then redissolved in dry toluene (10 mL). In a separate round bottom flask, 2,3-
Dichloro-5,6-dicyano-l,4-benzoquinone (DDQ) (90.0 mg, 0.396 mmol) was azeotroped with dry 
toluene and resuspended in dry toluene (5 mL). The dipyrromethane solution was cooled down 
to -78°C before the addition ofDDQ. The reaction mixture was allowed to proceed for 1 h. Once 
the oxidation was complete, DBU (0.306 mL, 2.05 mmol) and BF3·EhO (0.43 mL, 3.42 mmol) 
was added at -78°C. After 1 h, the reaction mixture was heated to 85°C for an additional 1.5 h. 
Allow the flask to cool to room temperature before filtering over celite and washing with 
dichloromethane. The products were purified by column chromatography using dichloromethane 
and the appropriate fractions collected. The product was isolated as a red solid (6.0 mg, 9 %). 
Found, in material recrystallized from aqueous methanol, C: 56.52, H: 3.66, N: 14.34; Calc: 
bH[CDCh]: 7.92 (2 H, s, H-3, H-5), 7.44 (1 H, s, H-8), 7.18 (2 H, d, J = 3.6 Hz, H-l, H-7), 6.57 
(2 H"d,J= 3.6 Hz, H-2, H-6). 
bc[CDCh]: 145.2 (C-3, C-5), 132.3 (C-8), 131.2 (C-l, C-7), 119.4 (C-2, C-6). 
bB[CDCh]: 0.31 (t, J = 29 Hz). 
bF[CDCh]: 145.2 (q, J = 29 Hz). 
Rf: 0.58 (Hexane-Diethyl ether 1: 1, v/v). 
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· -1- (2,3,4,6-0-Tetraacetyl-p-D-glucosyl)-dipyrromethane 99 
OAc 
2,3,4,6-0-Tetraacetyl-a-D-glucosyl-trichloroacetimidate 95 (0.50 g, 1.02 mmol) and 
dipyrromethane 106 (0.73 g, 4.99 mmol) were co-evaporated with dry toluene (10 mL) and 
redissolved in dry dichloromethane (15 mL). The solution was cooled to -20°C and boron 
trifluoride diethyl etherate (82.0 J,lL, 0.65 mmol) was added. After 20 min, the products were 
partitioned between dichloromethane (30 mL) and saturated aqueous sodium bicarbonate (30 
mL). The organic layer was dried (MgS04) and concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel. The appropriate fractions, which 
were eluted with dichloromethane-methanol (99:1, v/v), were combined and concentrated under 
reduced pressure to give 1-(2,3,4,6-0-tetraacetyl-fJ-D-glucosyl)dipyrromethane as a pale yellow 
foam (0.44 g, 91 %). Recrystallization of this material from aqueous methanol gave a colorless 
solid. Mp 67-68°C. 
Found, in material recrystallized from aqueous methanol: C, 58.10; H, 5.90; N, 5.75. Calc. for 
C23H28N209: C, 57.98; H, 5.92; N, 5.88%. 
EI-MS found M+ = 476.17948. C30 H22 Nt 0 5 requires: 476.17934. 
bH[CDCb]: 8.37 (1 H, s, N-Hl1), 8.19 (l H, s, N-HI0), 6.73 (l H, dd, J = 2.5 and 4.0 Hz, H-9), 
6.20 (1 H, dd, J = 2.8 and 5.8 Hz, H-8), 6.06 (2 H, m, H-3 and H-7), 5.92 (1 H, t, J = 2.8 Hz, H-
2), 5.33 (l H, t, J = 9.6 Hz, H-3 '), 5.15 (l H, t, J = 9.7 Hz, H-4'), 5.08 (1 H, t, J = 9.7 Hz, H-2'), 
4.40 (1 H, d, J = 9.8 Hz, H-l '), 4.30 (1 H, dd, J = 4.8 and 12.4 Hz, H-6"), 4.11 (1 H, dd, J = 1.9 
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-and 12.4 Hz, H-6'), 4.03 (1 H, d, J = 17.0 Hz, H-5'), 3.99 (1 H, d, J = 17.0 Hz, H-5), 3.81 (1 H, 
ddd, J = 2.0, 4.7 and 12.0 Hz, H-5'), 2.10 (3 H, s, CH3), 2.06 (3 H, s, CH3), 2.03 (3 H, s, CH3), 
1.92 (3 H, s, CH3). 
8c[CDCb]: 170.8 (OAc), 170.2 (OAc), 169.6 (OAc), 169.5 (OAc), 117.1 (C-9), 109.0 (C-3), 
108.4 (C-8), 107.2 (C-2), 106.0 (C-7), 76.1 (C-5'), 74.7 (C-1 '),73.6 (C-3'), 71.4 (C-2'), 68.5 (C-
4'), 62.6 (C-6'), 26.5 (CH2, C-5), 20.8 (CH3), 20.7 (CH3), 20.6 (CH3). 
Rf: 0.52 (Dichloromethane-Methanol 95:5, v/v). 
2,3,4,6-0-Tetraacetyl D-galactose 125 
OAcOAc ACO~OH 
OAc 
D-Galactose (5.00 g, 27.8 mmol) was dried under vacuo for 3 h at 40°C and was then 
dissolved in dry pyridine (50 mL), followed by addition of acetic anhydride (26.1 mL, 0.278 
mol). After stirring for 16 h at room temperature, the reaction was quenched with addition of 
methanol (10 mL). The solution was concentrated under reduced pressure and was then 
partitioned between dichloromethane (120 mL) and saturated aqueous sodium bicarbonate (100 
mL). The layers were separated and the aqueous layer was back-extracted with dichloromethane 
(2x20 mL). The combined organic layers were dried (MgS04) and concentrated under reduced 
pressure. The residue was redissolved in ethyl acetate (2 mL) and precipitated with cold hexane 
(100 mL) while stirring. The precipitate was collected by filtration to give 1,2,3,4,6-0-
pentaacetyl D-galactoside 126 as a white solid. This material (5.00 g, 12.8 mmol) was then 
dissolved in DMF (20 mL), followed by addition of hydrazine acetate (prepared by mixing 
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-hydrazine hydrate (0.75 mL) with acetic acid (1.43 mL) in dichloromethane (2.0 mL), 15.4 
mmol) slowly. After 45 min, the products were evaporated under reduced pressure and the 
residue was redissolved in dichloromethane (120 mL) and extracted with saturated aqueous 
sodium bicarbonate (100 mL). The layers were separated and the aqueous layer was back-
extracted with dichloromethane (2 x 20 mL). The combined organic layers were dried (MgS04) 
and concentrated under reduced pressure. The material was purified by column chromatography 
on silica gel. The appropriate fractions were eluted with dichloromethane-methanol (97:3, v/v) 
and the desired products were combined and evaporated under reduced pressure to give the title 
compound as a white foam (3.80 g, 85 %). 
oH[CDCb]: 5.42 (1 H, d, J= 3.1 Hz, H-1), 5.34 (1 H, t, J= 6.1 Hz, H-2), 5.10 (1 H, dd, J=3.1 
and 6.1 Hz, H-3), 4.42 (1 H, t, J = 9.1 Hz, H-4), 3.95 - 4.12(2 H, m, H-6, H-6'), 3.91 (1 H, t, J = 
6.1 Hz, H-5), 2.08 (3 H, s, CH3), 2.03 (3 H, s, CH3), 1.98 (3 H, s, CH3), 1.93 (3 H, s, CH3). 
Rr: 0.45 (Dichloromethane-MethanoI95:5, v/v). 
2,3,4,6-0-Tetraacetyl-a-n-galactosyl-trichloroacetimidate 127 
2,3,4,6-0-Tetraacetyl D-galactose 125 (3.00 g, 8.61 mmol) was co-evaporated with dry 
toluene (10 mL) and then dissolved in dry dichoromethane (20 mL). The reaction mixture was 
cooled to O°C (ice-water bath) and trichloroacetonitrile (10.4 mL, 0.103 mol) and DBU (0.36 
mL, 2.4 mmol) were added. After 1 h, the reaction mixture was washed with saturated aqueous 
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·sodium bicarbonate (70 mL). The layers were separated and the aqueous layer was back-
extracted with dichloromethane (2x 20 mL). The combined organic layers were dried (MgS04) 
and concentrated under reduced pressure. The residue was purified by column chromatography 
on silica gel. The products were eluted with toluene-ethyl acetate (3:1, v/v) and the appropriate 
fractions were collected and evaporated under reduced pressure to give the title compound as a 
white foam (3.31 g, 78%). 
bH[CDCb]: 8.67 (1 H, s, NH), 6.53 (1 H, d, J= 3.1 Hz, H-1), 5.49 (1 H, t, J= 3.1 Hz, H-4), 5.23 
- 5.41 (2 H, m, H-2, H-3), 4.38 (1 H, t, J= 3.1 Hz, H-5), 3.96 - 4.18 (2 H, m, H-6, H-6'), 2.10 (3 
H, s, CH3), 1.96 (3 H, s, CH3), 1.94 (3 H, s, CH3), 1.93 (3 H, s, CH3). 
Rf : 0.55 (Toluene-Ethyl acetate 1: 1, v/v). 
1- (2,3,4,6-0-Tetraacetyl-p-D-galactosyl)dipyrromethane 128 
2,3,4,6-0-Tetraacetyl-a-D-galactosyl-trichloroacetimidate 127 (0.13 g, 0.264 mmol) and 
dipyrromethane 106 (0.386 g, 2.64 mmol) were co-evaporated with dry toluene (10 mL) and re-
dissolved in dry dichloromethane (10 mL). The solution was cooled to -20°C and boron 
trifluoride diethyl etherate (22 ilL, 0.17 mmol) was added. After 20 min, the products were 
partitioned between dichloromethane (30 mL) and saturated aqueous sodium bicarbonate (30 
mL). The organic layer was dried (MgS04) and concentrated under reduced pressure. The 
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· -residue was purified by column chromatography on silica gel. The appropriate fractions, which 
were eluted with dichloromethane-methanol (99:1, v/v), were combined and concentrated under 
reduced pressure to give 1-(2,3,4,6-0-tetraacetyl-fJ-D-galactosyl)dipyrromethane as a pale 
yellow foam (0.11 g, 87%). 
EI-MS found M- = 476.17948. C30 H22 Nt Os requires: 476.17934. 
bH[CDCh]: 8.42 (1 H, s, N-H11), 8.27 (l H, s, N-H10), 6.74 (1 H, d, J = 4.0 Hz, H-9), 6.20 (1 H, 
dd, J = 2.4 and 5.4 Hz, H-8), 6.07 (2 H, m, H-4 and H-7), 5.93 (1 H, t, J = 2.8 Hz, H-3), 5.52 (1 
H, t, J = 9.2 Hz, H-4'), 5.32 (1 H, t, J = 9.3 Hz, H-3'), 5.08 (1 H, t, J = 9.3 Hz, H-2'), 4.38 (1 H, 
d,J=9.4Hz,H-1'),4.16(1 H,dd,J=4.4and 12.1 HZ,H-6"), 4.14 (l H,dd,J= 1.9 and 12.1 
Hz, H-6'), 4.07 (1 H, d, J = 17.0 Hz, H-5'), 4.02 (1 H, d, J = 16.6 Hz, H-5), 3.99 (l H, ddd, J = 
2.0, 4.3 and 12.0 Hz, H-5'), 2.21 (3 H, s, CH3), 2.08 (3 H, s, CH3), 2.03 (3 H, s, CH3), 1.93 (3 H, 
s, CH3). 
bc[CDCh]: 170.5 (OAc), 170.3 (OAc), 170.1 (OAc), 169.8 (OAc), 116.99 (C-9), 109.1 (C-3), 
108.4 (C-8), 107.2 (C-2), 105.8 (C-7), 75.2 (C-5'), 74.7 (C-1 '),71.6 (C-3'), 68.9 (C-2'), 67.7 (C-
4'), 61.7 (C-6'), 26.4 (CH2, C-5), 20.8 (CH3), 20.7 (CH3), 20.6 (CH3). 
Rf: 0.52 (Dichloromethane-MethanoI95:5, v/v). 
2,3,4,6-0-Tetraacetyl D-mannose 129 
OH 
D-Mannose (5.00 g, 27.8 mmol) was dried under vacuo for 3 h at 40°C and was then 
dissolved in dry pyridine (50 mL), followed by addition of acetic anhydride (26.1 mL, 0.278 
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· -mol). After stirring for 16 h at room temperature, the reaction was quenched with addition of 
methanol (10 mL). The solution was concentrated under reduced pressure and was then 
partitioned between dichloromethane (120 mL) and saturated aqueous sodium bicarbonate (100 
mL). The layers were separated and the aqueous layer was back-extracted with dichloromethane 
(2x20 mL). The combined organic layers were dried (MgS04) and concentrated under reduced 
pressure. The residue was redissolved in ethyl acetate (2 mL) and precipitated with cold hexane 
{l00 mL) while stirring. The precipitate was collected by filtration to give 1,2,3,4,6-0-
pentaacetyl D-mannoside 130 as a white solid. This material (5.0 g, 12.8mmol) was then 
dissolved in DMF (20 mL), followed by addition of hydrazine acetate (prepared by mixing 
hydrazine hydrate (0.75 mL) with acetic acid (1.43 mL) in dichloromethane (2.0 mL), 15.4 
mmol) slowly. After 45 min, the products were evaporated under reduced pressure and the 
residue was redissolved in dichloromethane (120 mL) and extracted with saturated aqueous 
sodium bicarbonate {l00 mL). The layers were separated and the aqueous layer was back-
extracted with dichloromethane (2x 20 mL). The combined organic layers were dried (MgS04) 
and concentrated under reduced pressure. The material was purified by column chromatography 
on silica gel. The appropriate fractions were eluted with dichloromethane-methanol (97:3, v/v) 
and the desired products were combined and evaporated under reduced pressure to give the title 
compound as a white foam (3.31 g, 74 %). 
bH[CDCh]: 5.45 (1 H, d, J= 3.1 Hz, H-l), 5.34 {l H, t, J= 6.1 Hz, H-4), 5.28 {l H, t, J= 9.1 Hz, 
H-2), 5.25 {l H, dd, J = 3.1 and 6.1 Hz, H-3), 4.24 - 4.28 (2 H, m, H-6, H-6'), 4.02 {l H, t, J = 
6.1 Hz, H-5), 2.17 (3 H, s, CH3), 2.11 (3 H, s, CH3), 2.06 (3 H, s, CH3), 2.01 (3 H, s, CH3). 
Rf: 0.45 (Dichloromethane-MethanoI95:5, v/v). 
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· -2,3,4,6-0-Tetraacetyl-a-D-mannosyl trichloroacetiinidate 131 
2,3,4,6-0-Tetraacetyl D-mannose 129 (3.00 g, 8.61 mmol) was co-evaporated with dry 
toluene (10 mL) and then dissolved in dry dichoromethane (20 mL). The reaction mixture was 
cooled to O°C (ice-water bath) and trichloroacetonitrile (l0.4 mL, 0.103 mol) and DBU (0.36 
mL, 2.4 mmol) were added. After 1 h, the reaction mixture was washed with saturated aqueous 
sodium bicarbonate (70 mL). The layers were separated and the aqueous layer was back-
extracted with dichloromethane (2 x 20 mL). The combined organic layers were dried (MgS04) 
and concentrated under reduced pressure. The residue was purified by column chromatography 
on silica gel. The products were eluted with toluene-ethyl acetate (3:1, v/v) and the appropriate 
fractions were collected and evaporated under reduced pressure to give the title compound as a 
white foam (3.01 g, 71 %). 
8H[CDCh]: 8.80 (1 H, s, NH), 6.29 (1 H, d, J= 3.1 Hz, H-l), 5.48 (1 H, t, J= 3.1 Hz, H-4), 5.40 
- 5.43 (2 H, m, H-2, H-3), 4.22 - 4.29 (2 H, m, H-6, H-6'), 4.14 (1 H, t, J = 3.1 Hz, H-5), 2.21 (3 
H, s, CH3), 2.09 (3 H, s, CH3), 2.08 (3 H, s, CH3), 2.02 (3 H, s, CH3). 
Rr: 0.55 (Toluene-Ethyl acetate 1: 1, v/v). 
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-1- (2,3,4,6-0-Tetraacetyl-a-D-mannosyl)dipyrromethane 132 
2,3,4,6-0-Tetraacetyl-a-D-mannosyl-trichloroacetimidate 131 (0.50 g, 1.02 mmol) and 
dipyrromethane 106 (0.73 g, 4.99 mmol) were co-evaporated with dry toluene (10 mL) and re-
dissolved in dry dichloromethane (15 mL). The solution was cooled to -20°C and boron 
trifluoride diethyl etherate (82 J,LI, 0.65 mmol) was added. After 20 min, the products were 
partitioned between dichloromethane (30 mL) and saturated aqueous bicarbonate (30 mL). The 
organic layer was dried (MgS04) and concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel. The appropriate fractions, which were eluted 
with dich10romethane-methanol (99:1, v/v) , were combined and concentrated under reduced 
pressure to give 1-(2,3,4,6-0-tetraacetyl-a-D-g1ucosyl)dipyrromethane as a pale yellow foam 
(0.35 g, 72%). 
EI-MS found M- = 476.17948. C30 H22 NJ 05 requires: 476.17934. 
oH[CDCh]: 8.26 (2 H, s, N-H11, N-H10), 6.78 (1 H, d, J= 1.4 Hz, H-9), 6.30 (1 H, m, H-8), 6.12 
(1 H, m, H-3), 6.00 (2 H, m, H-4 and H-7), 5.83 (1 H, t, J = 9.6 Hz, H-4'), 5.40 (1 H, t, J = 9.4 
Hz, H-3'), 5.03 (1 H, t, J = 9.4 Hz, H-2'), 4.28 (1 H, d, J = 9.4 Hz, H-1 '), 4.04 (1 H, dd, J = 4.4 
and 12.1 Hz, H-6" ), 4.01 (1 H, dd, J = 2.1 and 12.3 Hz, H-6'), 3.98 (1 H, d, J = 16.2 Hz, H-5 '), 
3.93 (1 H, d, J = 16.2 Hz, H-5), 3.68 (1 H, ddd, J = 3.0, 4.3 and 12.2 Hz, H-5'), 2.19 (3 H, s, 
CH3), 2.11 (3 H, s, CH3), 2.10 (3 H, s, CH3), 2.08 (3 H, s, CH3). 
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-bc[CDCb]: 170.9 (OAc), 170.3 (OAc), 170.2 (OAc), 169.8 (OAc), 117.4 (C-9), 108.9 (C-3), 
108.4 (C-8), 108.3 (C-2), 106.8 (C-7), 72.6 (C-5'), 71.0 (C-1 '),70.4 (C-3'), 70.3 (C-2'), 68.9 (C-
4'), 66.6 (C-6'), 26.4 (CH2, C-5), 21.0 (CH3), 20.7 (CH3), 20.6 (CH3). 
Rr: 0.52 (Dichloromethane-Methanol 95:5, v/v). 
5-Isopropyl-2,2' -dipyrromethane 109 
Pyrrole 96 (11.4 mL, 0.164 mol) and isobutyric aldehyde 108 (0.6 mL, 6.6 mmol) were 
flushed with argon followed by addition of trifluoroacetic acid (0.12 mL, 1.6 mmol) slowly. 
After 5 min, the reaction was quenched with sodium hydroxide solution (80 mL, 0.1 M). The 
reaction mixture was extracted with ethyl acetate (100 mL). The organic layer was separated, 
dried (MgS04), and filtered. The filtrate was then evaporated under reduced pressure and 
purified by column chromatography on silica. The products were eluted with dichloromethane 
and the appropriate fractions were combined and evaporated under reduced pressure to give the 
title compound as a white solid (0.82 g, 66%). 
bH[CDCb]: 7.85 (2 H, s, br, NH), 6.60 - 6.70 (2 H, m, H-1, H-1 '),6.12 - 6.22 (2 H, m, H-3, H-
3'),6.04 - 6.12 (2 H, m, H-2, H-2'), 3.81 (1 H, d, J = 9.1 Hz, CH), 2.26 - 2.41 (1 H, m, CH), 
0.97 (6 H, d, J = 6.1 Hz, CH3). 
Rr: 0.54 (Hexane-Diethyl ether 1: 1, v/v). 
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· -4,4-Difluoro-4-bora-8-isopropyl-3a,4a-diaza-s-indacene 110 
5-Isopropyl-2,2'-dipyrromethane 109 (188.0 mg, 1.0 mmol) was co-evaporated with dry 
toluene (5 mL) and redissolved in dichloromethane (10 mL). In another flask, DDQ (238.0 mg, 
1.05 mmol) was co-evaporated with dry toluene (5 mL) and redissolved in dichloromethane (5 
mL). DDQ solution was added drop-wise to 5-isopropyl dipyrromethane solution at -30°C. The 
reaction was allowed to proceed for 1 h at -30°C before addition of DBU (0.9 mL, 6.0 mmol) 
and Boron trifluoride etherate (1.3 mL, 10.0 mmol). The solution was then refluxed for 1 hand 
was allowed to cool to room temperature. The solution was reduced under pressure followed by 
column chromatography. Evaporation of appropriate fractions, which were eluted with 
dichloromethane yielded the title compound (84.0 mg, 36%). Recrystallization from hexane gave 
small red crystals. Mp 105-1 06oC. 
bH[CDCb]: 7.95 (2 H, s, H-3, H-5), 7.39 -7.46 (2 H, m, H-l, H-7), 6.51 - 6.58 (2 H, ill, H-2, H-
6), 3.42 - 3.59 (l H, m, CH), 1.57 (6 H, d, J = 6.1 Hz, CH3). 
Rr: 0.60 (Hexane-Diethyl ether 1: 1, v/v). 
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-2,3,5-0-Triacetyl ribose 112 
ACOi .____o-...... ~ ~OH 
OAc OAc 
D-Ribose 91 (1.00 g, 6.67 mmol) was dried under vacuo for 3 h at 40°C and was then 
dissolved in dry pyridine (30 mL), followed by addition of acetic anhydride (0.63 mL, 66.7 
mmol). After stirring for 16 h at room temperature, the reaction was quenched with addition of 
methanol (5 mL). The solution was concentrated under reduced pressure and was then 
partitioned between dichloromethane (50 mL) and saturated aqueous sodium bicarbonate (40 
mL). The layers were separated and the aqueous layer was back-extracted with dichloromethane 
(2x20 mL). The combined organic layers were dried (MgS04) and concentrated under reduced 
pressure. The residue was redissolved in ethyl acetate (2 mL) and precipitated with cold hexane 
(50 mL) while stirring. The precipitate was collected by filtration to give 1,2,3,5-0-tetraacetyl 
ribose 111 as a white solid. This solid (2.00 g, 6.3 mmol) was then redissolved in DMF (10 mL) 
followed by addition of ammonium acetate (0.97 g, 12.6 mmol) and stirred overnight at room 
temperature. The reaction solution was then partitioned between ethyl acetate (70 mL) and 
distilled water (60 mL). The organic layer was dried (MgS04) and concentrated under reduced 
pressure. The residue was purified by column chromatography and the products eluted with 
dichloromethane-methanol (99: 1, v/v). The appropriate fractions were collected and evaporated 
under reduced pressure to give the title compound (0.52 g, 30%). 
DH[CDCh]: 5.52 - 5.56 (1 H, m, H-l '),5.09 - 5.18 (1 H, m, H-2'), 4.92 - 4.99 (1 H, m, H-3'), 
4.06 - 4.16 (1 H, m, H-4'), 3.77 - 3.88 (2 H, m, H-5', H-5"), 2.14 (3 H, s, CH3), 2.12 (3 H, s, 
CH3), 2.10 (3 H, s, CH3). 
Rf: 0.40 (Dichloromethane-Methano195:5, v/v). 
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2,3,5-0-Triacetyl ribosyl-trichloroacetimidate 113 
AC0'q o NH 
O~ 
OAc OAc CCI3 
2,3,5-0-Triacetyl ribose 112 (0.50 g, 1.8 mmol) was co-evaporated with dry toluene (10 
mL) and then dissolved in dry dichoromethane (10 mL). The reaction mixture was cooled to O°C 
(ice-water bath) and trichloroacetonitrile (2.2 mL, 22.0 mmol) and DBU (0.11 mL, 0.72mmol) 
were added. After 1 h, the reaction mixture was washed with saturated aqueous sodium 
bicarbonate (50 mL). The layers were separated and the aqueous layer was back-extracted with 
dichloromethane (2 x20 mL). The combined organic layers were dried (MgS04) and concentrated 
under reduced pressure. The residue was purified by column chromatography on silica gel. The 
products were eluted with toluene-ethyl acetate (3:1, v/v) and the appropriate fractions were 
collected and evaporated under reduced pressure to give the title compound as a white foam 
(0.45 g, 60%). 
oH[CDCb]: 8.77 (l H, s, NH), 6.27 (l H, d, J = 3.6 Hz, H-l '), 5.50 (1 H, t, J = 3.6 Hz, H-2'), 
5.25 - 5.31 (2 H, ill, H-3', H-4'), 3.99 - 4.02 (2 H, ill, H-5', H-5"), 2.17 (3 H, s, CH3), 2.15 (3 H, 
oc[CDCb]: 170.1 (OAc), 169.7 (OAc), 169.6 (OAc), 160.3 (C=NH), 95.1 (C-l), 66.6 (C-2), 66.2 
(C-3), 65.6 (C-4), 63.3 (C-5), 20.9 (CH3), 20.8 (CH3), 20.7 (CH3). 
Rf : 0.50 (Toluene-Ethyl acetate 1:1, v/v). 
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· -4,4-Difluoro-4-bora-1,3,5, 7-tetramethyl-8-(5-bromopentyl)-3a,4a-diaza-s-indacene 117 
A solution of 6-bromohexanoyl chloride 115 (0.56 mL, 3.7 mmol) in dry 
dichloromethane (25 mL) was added dropwise over a period of 5 min to a solution of 2,4-
dimethylpyrrole 116 (1.0 mL, 9.7 mmol) in dry dichloromethane (10 mL). The mixture was 
heated under reflux for 3 h and then concentrated to dryness under reduced pressure. The residue 
was dissolved in dry dichloromethane (l0 mL) followed by addition of dry hexane (l00 mL). 
After the mixture was left at -4°C overnight, the supernatant was decanted and the residue was 
washed with cold hexane (2x20 mL) and then dissolved in dry toluene (30 mL). Dry 
triethylamine (1.0 mL, 7.2 mmol) was added and the reaction mixture was stirred for 15 min. 
Boron trifluoride diethyl etherate (1.2 mL, 9.6 mmol) was then added and the mixture was heated 
at 40°C for 3 h. Upon cooling to room temperature, the products were washed successively with 
water (30 mL) and brine (3x30 mL). The organic layer was dried (MgS04) and concentrated 
under reduced pressure to gIve a dark red oil. The mixture was purified by column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane-hexane (l: 1, v Iv), were pooled and concentrated under reduced pressure to 
yield the title compound as a bright orange solid (0.78 g, 62%). 
FAB-MS found M+ = 396.118, C18H24BBrF2N2: 396.120 
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-oH[CDCb]: 6.08 (2 H, s, H-2, H-6), 3.46 (2 H, t, J = 6.6 Hz, CH2), 2.99 (2 H, m, Br-CH2), 2.54 
(6 H, s, CH3), 2.44 (6 H, s, CH3), 1.96 (2 H, t, J 5.4 Hz, CH2), 1.69 - 1.72 (4 H, m, CH2, CH2). 
oc[CDCb]: 121.7 (C-2, C-6), 58.5 (Br-C), 33.4 (CH2), 32.2 (CH2), 32.1 (CH2), 30.9 (CH2), 28.6 
(CH2), 16.5 (CH3), 14.5 (CH3). 
Rf : 0.57 (Hexane-Diethyl ether 1: 1, v/v). 
4,4-Difluoro-4-bora-1,3,5, 7 -tetramethyl-S-(5-hydroxypentyl)-3a,4a-diaza-s-indacene 119 
4,4-Difluoro-4-bora-1,3,5,7-tetramethyl-8-(5-bromopentyl)-3a,4a-diaza-s-indacene 117 
(0.20 g, 0.60 mmol) and potassium acetate (0.17 g, 1.72 mmol) were purged with nitrogen in a 
septum-capped flask. The solids were then dissolved in dry DMF (10 mL) and stirred at 50°C for 
3 d. After the products were cooled to room temperature, ethyl acetate (50 mL) was added and 
the resulting mixture was washed successively with distilled water (50 mL) and brine (3 x 50 
mL). The organic layer was dried (MgS04) and concentrated under reduced pressure and the 
products (4,4-difluoro-4-bora-1,3,5, 7 -tetramethyl-8-( 5 -acetoxypentyl)-3a,4a-diaza-s-indacene, 
lIS) were used for the next step without further purification. The residue above was dissolved in 
a mixture ofTHF-methanol (10 mL, 2:8 v/v) and sparged with nitrogen for 15 min. In a separate 
flask, lithium hydroxide monohydrate (41 mg, 0.98 mmol) was dissolved in distilled water (5 
mL) and sparged with nitrogen for 15 min. The latter solution was then added drop-wise to the 
former over 5 min. After 3 h, the products were concentrated to dryness under reduced pressure 
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-and the residue was purified by column chromatography on silica gel. The appropriate fractions, 
which were eluted with dichloromethane-methanol (98:2, v/v) were combined and concentrated 
under reduced pressure to give the title compound as a bright orange solid (98 mg, 50%). 
oH[CDCh]: 6.07 (2 H, s, H-2, H-6), 3.71 (2 H, t, J = 5.4 Hz, CH2), 3.00 (2 H, m, Br-CH2), 2.54 
(6 H, s, CH3), 2.44 (6 H, s, CH3), 1.71 (2 H, t, J = 8.4 Hz, CH2), 1.60 - 1.69 (4 H, m, CH2), 
1.31(1 H, s, OH). 
oc[CDCh]: 121.6 (C-2, C-6), 62.7 (Br-C), 32.4 (CH2), 31.7 (CH2), 29.7 (CH2), 28.4 (CH2), 26.6 
(CH2), 16.4 (CH3), 14.5 (CH3). 
Rf: 0.46 (Dichloromethane-Methanol 95:5, v/v). 
1-( 4,4-Difluoro-4-bora-l,3,5, 7-tetramethyl-3a,4a-diaza-s-indacen-8-yl)heptane-5-0-(2-
cyanoethyl) N,N-diisopropylphosphoramidite 120 
4,4-Difluoro-4-bora-1,3,5,7-tetramethyl-8-(5-hydroxypentyl)-3a,4a-diaza-s-indacene 119 
(0.40 g, 1.20 mmol) was co-evaporated with dry toluene (7 mL) and redissolved in dry THF (10 
mL). N,N-Diisopropylethylamine (0.46 mL, 2.64 mmol) followed by N,N-di is opropyl 
phosphochloridite 70 (0.45 g, 1.92 mmol) were added to the reaction mixture and the reaction 
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-was allowed to proceed for 30 min at room temperature. The products were then concentrated 
under reduced pressure and purified by column chromatography on silica gel. The appropriate 
fractions, which were eluted with acetone-hexane-triethylamine (20:78:2, v/v) were combined 
and evaporated under reduced pressure to yield the phosphoramidite as a bright orange oil (0.33 
g,52%). 
DH[CDCh]: 6.07 (2 H, s, H-2, H-6), 3.62 - 3.66 (2 H, m, CH2), 2.95 (2 H, m, Br-CH2), 2.53 (6 H, 
s, CH3), 2.43 (6 H, s, CH3), 1.66 (2 H, t, J = 8.4 Hz, CH2), 1.58 - 1.64 (4 H, m, CH2, CH2). 
Dp[CDCh]:149.9 
Rr: 0.3 8 (Dichloromethane) 
4,4-Dimethoxy-4-bora-1,3,5, 7-tetramethyl-8-(5-bromopentyl)-3a,4a-diaza-s-indacene 121 
4,4-Difluoro-4-bora-l,3,5, 7-tetramethyl-8-(5-bromopentyl)-3a,4a-diaza-s-indacene 117 
(25 mg, 0.075 mmol) and aluminum chloride (13 mg, 0.097 mmol) were dissolved in dry 
dichloromethane (10 mL) and heated to 45°C for 5 min. The reaction mixture was cooled to 
room temperature followed by addition of dry methanol (5 mL). After 10 min, the products were 
concentrated to dryness under reduced pressure. The residue was purified by column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
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-dichloromethane-methanol (98:2, v/v) were combined and evaporated under reduced pressure to 
give the title compound as an orange solid (26 mg, 83%). 
bH[CDCb]: 6.06 (2 H, s, H-2, H-6), 3.50 (2 H, m, CH2), 2.99 (2 H, m, Br-CH2), 2.83 (6 H, s, 0-
CH3) 2.51 (6 H, s, CH3), 2.45 (6 H, s, CH3), 1.96 (2 H, t, J= 5.4 Hz, CH2), 1.67 - 1.71 (4 H,m, 
CH2). 
Rf : 0.30 (Dichloromethane-MethanoI95:5, v/v) 
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Appendix 
AI: 1.0 Jlmol RNA synthesis cycle 
## Tet times for pushing amidite to each column 
TTIME 1 3.9 
TTIME 2 4.1 
TTIME 3 4.3 
TTIME 4 4.5 
## Couple time for each base, and a default time for those not specified 
CTIMEA 600 
CTIME G 600 
CTIME C 600 
CTIME T 600 
CTIME 5 600 
CTIME 6 600 
CTIME 7 600 
CTIME 8 600 
CTIME Default 600 
## PROCEDURE: BEGin 
## PURPOSE: Invoked once at the beginning of the rUD, to prime the delivery lines. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW BEGin $Col <multiline> 
TRANsfer Pressure( Amidite, Tet) 15 
TRANsfer AToWaste 3 
TRANsfer GToWaste 3 
TRANsfer CToWaste 3 
TRANsfer TToWaste 3 
TRANsfer TetToWaste 5 
TRANsfer PressureCapAB 8 
TRANsfer CapAToWaste 5 
TRANsfer CapBToWaste 5 
TRANsfer Pressurelodine 5 
TRANsfer IodineTo Waste 5 
TRANsfer PressureTCA 15 
TRANsfer TCAToWaste 10 
TRANsfer Pres sureD CM 15 
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TRANsfer DCMToWaste 10 
TRANsfer PressureACN 15 
TRANsfer ACNToWaste 10 
TRANsfer ACNToColumn($Col) 10 
TRANsfer ReverseFlush($Col) 10 
TRANsfer BlockFlush 10 
TRANsfer BlockVent 3 
## PROCEDURE: DETRitylate 
## PURPOSE: Deprotection routine, invoked at every base addition and optionally at 
the end of the synthesis run. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW DETRitylate $Col <multiline> 
TRANsfer BlockVent 2 
TRANsfer PressureTCA 3 
TRANsfer PressureACN 3 
TRANsfer PressureDCM 3 
TRANsfer DCMToCWaste($Col) 42 
SAFe No 
MONitor TCAToCWaste($Col) 110 
TRANsfer FlushToCWaste($Col) 7 
TRANsfer ACNToCWaste($Col) 15 
TRANsfer Flush ToCWaste($Col) 7 
TRANsfer ACNToCWaste($Col) 15 
TRANsfer ReverseFlush($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer FlushToColumn($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer ReverseFlush($Col) 10 
TRANsfer ACNToWaste 4 
TRANsfer BlockFlush 6 
SAFe Yes 
## PROCEDURE: PREPare 
## PURPOSE: Prepare for amidite delivery. Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW PREPare $Col <multiline> 
TRANsfer BlockVent 2 
TRANsfer Pressure(Amidite,Tet) 3 
## PROCEDURE: DELIVer 
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-## PURPOSE: Amidite delivery procedure. Invoked once for each active column, at 
every base addition. 
$Col - A single column ## INPUTS: 
## 
## 
$Base - A single base to be delivered into the column 
$TTime - Amidite delivery time (Set with TTIME) 
NEW DELIVer $Col $Base $TTime <multiline> 
TRANsfer TetToColumn($Col) 1.7 
TRANsfer ($Base,Tet)ToColumn($Col) 5.0 
TRANsfer TetToColumn($Col) $TTime 
TRANsfer FlushToColumn($Col) 1 
## PROCEDURE: COUPle 
## PURPOSE: Coupling procedure, Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
## $CTime - Coupling time (Set with CTIME) 
NEW COUPle $Col $CTime <multiline> 
SLEep $CTime 
TRANsfer ACNToWaste 4 
TRAN sfer ReverseFlush($Col) 8 
TRAN sfer BlockFlush 5 
## PROCEDURE: CAP 
## PURPOSE: Cap synthesis columns. Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW CAP $Col <multiline> 
TRANsfer BlockVent 2 
TRANsfer PressureCapAB 3 
TRANsfer CapABToColumn($Col) 12 
SLEep 6 
TRANsfer ACNToWaste 4 
TRANsfer ReverseFlush($Col) 8 
TRANsfer BlockFlush 6 
## PROCEDURE: OXiDize 
## PURPOSE: Oxidization routine, invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW OXIDize $Col <multiline> 
TRANsfer BlockVent 
TRANsfer PressureACN 
TRAN sfer PressureIodine 
2 
3 
3 
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TRANsfer IodineToColumn($Col) 12 
TRANsfer BlockFlush 4 
SLEep 20 
TRANsfer ReverseFlush($Col) 8 
TRANsfer ACNToWaste 4 
TRANsfer ACNToColumn($Col) 15 
TRANsfer FlushToColumn($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer ReverseFlush($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer FlushToColumn($Col) 10 
TRANsfer BlockFlush 6 
## PROCEDURE: WASH 
## PURPOSE: Clean up delivery lines after a run has been terminated. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW WASH $Col <multiline> 
SAFe Yes 
TRANsfer ReverseFlush($Col) 15 
TRANsfer BlockFlush 3 
TRANsfer ACNToColumn($Col) 20 
TRANsfer ReverseFlush($Col) 15 
TRANsfer BlockFlush 3 
TRANsfer ACNToColumn($Col) 20 
TRANsfer FlushToColumn($Col) 15 
TRANsfer ACNToWaste 4 
TRANsfer BlockFlush 8 
END 
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· -A2: 0.2 J.1mol RNA synthesis cycle 
## Tet times for pushing amidite to each column 
TTIME 1 3.0 
TTIME2 3.2 
TTIME 3 3.4 
TTIME4 3.6 
## Couple time for each base, and a default time for those not specified 
CTIMEA 600 
CTIME G 600 
CTIME C 600 
CTIME T 600 
CTIME 5 600 
CTIME 6 600 
CTIME 7 600 
CTIME 8 600 
CTIME Default 600 
## PROCEDURE: BEGin 
## PURPOSE: Invoked once at the beginning of the run, to prime the delivery 
lines. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW BEGin $Col <multiline> 
TRANsfer Pressure( Amidi te, Tet) 15 
TRANsfer AToWaste 3 
TRANsfer GToWaste 3 
TRANsfer CToWaste 3 
TRANsfer TToWaste 3 
TRANsfer TetToWaste 5 
TRANsfer PressureCapAB 8 
TRANsfer CapATo Waste 5 
TRANsfer CapBToWaste 5 
TRANsfer PressureIodine 5 
TRANsfer IodineToWaste 5 
TRANsfer PressureTCA 15 
TRANsfer TCAToWaste 10 
TRANsfer PressureDCM 15 
TRANsfer DCMToWaste 10 
TRANsfer PressureACN 15 
TRANsfer ACNToWaste 10 
, I 
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TRANsfer ACNToColumn($Col) 10 
TRAN sfer ReverseFlush($Col) 10 
TRAN sfer BlockFlush 10 
TRANsfer BlockVent 3 
## PROCEDURE: DETRitylate 
## PURPOSE: Deprotection routine, invoked at every base addition and 
optionally at the end of the synthesis run. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW DETRitylate $Col <multiline> 
TRANsfer BlockVent 2 
TRANsfer PressureTCA 3 
TRANsfer PressureACN 3 
TRANsfer PressureDCM 3 
TRANsfer DCMToCWaste($Col) 32 
SAFe No 
MONitor TCA ToCWaste($Col) 60 
TRANsfer Flush ToCWaste($Col) 7 
TRANsfer ACNToCWaste($Col) 14 
TRANsfer FlushToCWaste($Col) 7 
TRANsfer ACNToCWaste($Col) 14 
TRANsfer ReverseFlush($Col) 7 
TRANsfer ACNToColumn($Col) 14 
TRANsfer FlushToColumn($Col) 7 
TRANsfer ACNToColumn($Col) 14 
TRANsfer ReverseFlush($Col) 10 
TRANsfer ACNToWaste 4 
TRANsfer BlockFlush 6 
SAFe Yes 
## PROCEDURE: PREPare 
## PURPOSE: Prepare for amidite delivery. Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW PREPare $Col <multiline> 
TRANsfer BlockVent 2 
TRANsfer Pressure(Amidite,Tet) 3 
## PROCEDURE: DELIVer 
## PURPOSE: Amidite delivery procedure. Invoked once for each active column, 
at every base addition. 
## INPUTS: $Col - A single column 
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-## 
## 
$Base - A single base to be delivered into the column 
$TTime - Amidite delivery time (Set with TTIME) 
NEW DELIVer $Col $Base $TTime <multiline> 
TRANsfer TetToColumn($Col) 1.7 
TRANsfer ($Base,Tet)ToColumn($Col) 3.5 
TRANsfer TetToColumn($Col) $TTime 
TRAN sfer TetTo Waste 1 
TRANsfer FlushToColumn($Col) 1 
## PROCEDURE: COUPle 
## PURPOSE: Coupling procedure, Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
## $CTime - Coupling time (Set with CTIME) 
NEW COUPle $Col $CTime <multiline> 
SLEep $CTime 
TRANsfer ACNToWaste 4 
TRAN sfer ReverseFlush($Col) 8 
TRAN sfer BlockFlush 5 
## PROCEDURE: CAP 
## PURPOSE: Cap synthesis columns. Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW CAP $Col <multiline> 
TRANsfer BlockVent 2 
TRAN sfer PressureCapAB 3 
TRANsfer CapABToColumn($Col) 12 
SLEep 6 
TRANsfer ACNToWaste 4 
TRAN sfer ReverseFlush($Col) 8 
TRAN sfer BlockFlush 6 
## PROCEDURE: OXIDize 
## PURPOSE: Oxidization routine, invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW OXIDize $Col <multiline> 
TRANsfer BlockVent 2 
TRAN sfer PressureIodine 3 
TRANsfer IodineToColumn($Col) 12 
TRAN sfer BlockFlush 4 
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SLEep 20 
TRANsfer ReverseFlush($Col) 6 
TRANsfer ACNToWaste 4 
TRANsfer ACNToColumn($Col) 14 
TRANsfer FlushToColumn($Col) 6 
TRANsfer ACNToColumn($Col) 14 
TRANsfer ReverseFlush($Col) 6 
TRANsfer ACNToColumn($Col) 14 
TRANsfer Flush ToColumn($Col) 9 
TRANsfer BlockFlush 6 
##PROCEDURE: WASH 
## PURPOSE: Clean up delivery lines after a run has been terminated. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW WASH $Col <multiline> 
SAFe Yes 
TRANsfer ReverseFlush($Col) 15 
TRANsfer BlockFlush 3 
TRANsfer ACNToColumn($Col) 20 
TRANsfer ReverseFlush($Col) 15 
TRANsfer BlockFlush 3 
TRANsfer ACNToColumn($Col) 20 
TRANsfer Flush ToColumn($Col) 15 
TRANsfer ACNToWaste 4 
TRANsfer BlockFlush 8 
END 
157 
-A3: Finall p.1mol RNA synthesis cycle with sparging and base wash 
## Tet times for pushing amidite to each column 
TTIME 1 3.9 
TTIME 2 4.1 
TTIME 3 4.3 
TTIME 4 4.5 
## Couple time for each base, and a default time for those not specified 
CTIMEA 30 
CTIMEG 30 
CTIMEC 30 
CTIME T 30 
CTIME 5 30 
CTIME6 30 
CTIME 7 30 
CTIME 8 30 
CTIME Default 30 
## PROCEDURE: BEGin 
## PURPOSE: Invoked once at the beginning of the run, to prime the delivery 
lines. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW BEGin $Col <multiline> 
TRANsfer Pressure( Amidite, Tet) 15 
TRANsfer AToWaste 3 
TRANsfer GToWaste 3 
TRANsfer CToWaste 3 
TRANsfer TToWaste 3 
TRANsfer TetToWaste 5 
TRANsfer PressureCapAB 8 
TRANsfer CapATo Waste 5 
TRANsfer CapBToWaste 5 
TRANsfer PressureIodine 5 
TRANsfer IodineToWaste 5 
TRANsfer PressureTCA 15 
TRANsfer TCAToWaste 10 
TRANsfer PressureDCM 15 
TRANsfer DCMToWaste 10 
TRANsfer PressureACN 15 
I 
J 
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TRANsfer ACNToWaste 10 
TRAN sfer ACNToColumn($Col) 10 
TRAN sfer ReverseFlush($Col) 10 
TRAN sfer BlockFlush 10 
TRANsfer BlockVent 3 
## PROCEDURE: DETRitylate 
## PURPOSE: Deprotection routine, invoked at every base addition and 
optionally at the end of the synthesis run. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW DETRitylate $Col <multiline> 
TRANsfer BlockVent 2 
TRANsfer PressureTCA 3 
TRANsfer PressureACN 3 
TRANsfer PressureDCM 3 
TRANsfer DCMToCWaste($Col) 42 
SAFe No 
MONitor TCA ToCWaste($Col) 60 
TRANsfer FlushToCWaste($Col) 7 
TRANsfer ACNToCWaste($Col) 15 
TRANsfer FlushToCWaste($Col) 7 
TRANsfer ACNToCWaste($Col) 15 
TRANsfer ReverseFlush($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer FlushToColumn($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer ReverseFlush($Col) 10 
TRANsfer ACNToWaste 4 
TRANsfer BlockFlush 6 
SAFe Yes 
TRANsfer BlockVent 3 
TRANsfer PressureACN 3 
TRANsfer PressureAux 3 
TRANsfer AuxToColumn($Col) 30 
TRANsfer FlushToCWaste($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer FlushToCWaste($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer ReverseFlush($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer FlushToColumn($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer ReverseFlush($Col) 10 
TRANsfer ACNToWaste 4 
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TRAN sfer BlockFlush 6 
## PROCEDURE: PREPare 
## PURPOSE: Prepare for amidite delivery. Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW PREPare $Col <multiline> 
TRANsfer BlockVent 2 
TRANsfer Pressure(Amidite,Tet) 3 
## PROCEDURE: DELIVer 
## PURPOSE: Amidite delivery procedure. Invoked once for each active 
column, at every base addition. 
$Col - A single column ## INPUTS: 
## 
## 
$Base - A single base to be delivered into the column 
$TTime - Amidite delivery time (Set with TTIME) 
NEW DELIVer $Col $Base $TTime <multiline> 
TRANsfer TetToColumn($Col) 1.7 
TRANsfer ($Base,Tet)ToColumn($Col) 5.0 
TRANsfer TetToColumn($Col) $TTime 
TRAN sfer FlushToColumn($Col) 1 
## PROCEDURE: COUPle 
## PURPOSE: Coupling procedure, Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
## $CTime - Coupling time (Set with CTIME) 
NEW COUPle $Col $CTime <multiline> 
SLEep 15 
TRANsfer FlushToColumn($Col) 1 
SLEep 10 
TRANsfer FlushToColumn($Col) 1 
SLEep 5 
TRANsfer ACNToWaste 4 
TRAN sfer ReverseFlush($Col) 8 
TRAN sfer BlockFlush 5 
## PROCEDURE: CAP 
## PURPOSE: Cap synthesis columns. Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW CAP $Col <multiline> 
TRANsfer BlockVent 
TRAN sfer PressureCapAB 
2 
3 
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TRANsfer CapABToColumn($Col) 12 
SLEep 6 
TRANsfer ACNToWaste 4 
TRAN sfer ReverseFlush($Col) 8 
TRAN sfer BlockFlush 6 
## PROCEDURE: OXIDize 
## PURPOSE: Oxidization routine, invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW OXIDize $Col <multiline> 
TRANsfer BlockVent 2 
TRANsfer PressureACN 3 
TRANsfer Pressurelodine 3 
TRANsfer IodineToColumn($Col) 12 
TRANsfer BlockFlush 4 
SLEep 20 
TRANsfer ReverseFlush($Col) 8 
TRANsfer ACNToWaste 4 
TRANsfer ACNToColumn($Col) 15 
TRANsfer FlushToColumn($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer ReverseFlush($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer FlushToColumn($Col) 10 
TRANsfer BlockFlush 6 
## PROCEDURE: WASH 
## PURPOSE: Clean up delivery lines after a run has been terminated. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW WASH $Col <multiline> 
SAFe Yes 
TRANsfer ReverseFlush($Col) 15 
TRANsfer BlockFlush 3 
TRANsfer ACNToColumn($Col) 20 
TRANsfer ReverseFlush($Col) 15 
TRANsfer BlockFlush 3 
TRANsfer ACNToColumn($Col) 20 
TRANsfer FlushToColumn($Col) 15 
TRANsfer ACNToWaste 4 
TRANsfer BlockFlush 8 
END 
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· -A4: 1.0 J.1mol DNA synthesis cycle 
## Tet times for pushing amidite to each column 
TTIME 1 3.9 
TTIME 2 4.1 
TTIME 3 4.3 
TTIME 4 4.5 
## Couple time for each base, and a default time for those not specified 
CTIMEA 20 
CTIME G 20 
CTIME C 20 
CTIME T 20 
CTIME 5 300 
CTIME 6 300 
CTIME 7 300 
CTIME 8 300 
CTIME Default 20 
## PROCEDURE: BEGin 
## PURPOSE: Invoked once at the beginning of the rUD, to prime the delivery lines. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW BEGin $Col <multiline> 
TRANsfer Pressure(Amidite, Tet) 15 
TRANsfer AToWaste 3 
TRANsfer GToWaste 3 
TRANsfer CToWaste 3 
TRANsfer TToWaste 3 
TRANsfer TetToWaste 5 
TRANsfer PressureCapAB 8 
TRANsfer CapAToWaste 5 
TRANsfer CapBTo Waste 5 
TRANsfer PressureIodine 5 
TRANsfer IodineToWaste 5 
TRANsfer PressureTCA 15 
TRANsfer TCAToWaste 10 
TRANsfer PressureDCM 15 
TRANsfer DCMToWaste 10 
TRANsfer PressureACN 15 
TRANsfer ACNToWaste 10 
TRANsfer ACNToColumn($Col) 10 
162 
TRAN sfer ReverseFlush($Col) 
TRANsfer BlockFlush 
TRANsfer BlockVent 
## PROCEDURE: DETRitylate 
10 
10 
3 
## PURPOSE: Deprotection routine, invoked at every base addition and optionally 
at the end of the synthesis run. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW DETRitylate $Col <multiline> 
TRANsfer BlockVent 2 
TRANsfer PressureTCA 2 
TRANsfer PressureACN 2 
TRANsfer PressureDCM 2 
TRANsfer DCMToCWaste($Col) 25 
SAFe No 
MONitor TCAToCWaste($Col) 110 
TRANsfer FlushToCWaste($Col) 7 
TRANsfer ACNToCWaste($Col) 12 
TRANsfer FlushToCWaste($Col) 7 
TRANsfer ACNToCWaste($Col) 12 
TRANsfer ReverseFlush($Col) 7 
TRANsfer ACNToColumn($Col) 12 
TRANsfer ReverseFlush($Col) 9 
TRANsfer ACNToWaste 2 
TRANsfer BlockFlush 5 
SAFe Yes 
# PROCEDURE: PREPare 
## PURPOSE: Prepare for amidite delivery. Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW PREPare $Col <multiline> 
TRAN sfer Block Vent 2 
TRANsfer Pressure(Amidite,Tet) 3 
## PROCEDURE: DELIVer 
## PURPOSE: Amidite delivery procedure. Invoked once for each active 
## INPUTS: 
## 
## 
column, at every base addition. 
$Col - A single column 
$Base - A single base to be delivered into the column 
$TTime - Amidite delivery time (Set with TTIME) 
NEW DELIVer $Col $Base $TTime <multiline> 
TRANsfer TetToColumn($Col) 1.7 
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TRANsfer ($Base,Tet)ToColumn($Col) 
TRANsfer TetToColumn($Col) 
TRAN sfer FlushToColumn($Col) 
## PROCEDURE: COUPle 
5.0 
$TTime 
1 
## PURPOSE: Coupling procedure, Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
## $CTime - Coupling time (Set with CTIME) 
NEW COUPle $Col $CTime <multiline> 
SLEep $CTime 
TRANsfer ACNToWaste 4 
TRAN sfer ReverseFlush($Col) 8 
TRAN sfer BlockFlush 5 
## PROCEDURE: CAP 
## PURPOSE: Cap synthesis columns. Invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW CAP $Col <multiline> 
TRANsfer BlockVent 2 
TRAN sfer PressureCapAB 2 
TRANsfer CapABToColumn($Col) 12 
SLEep 6 
TRANsfer ACNToWaste 4 
TRAN sfer ReverseFlush($Col) 8 
TRAN sfer BlockFlush 5 
## PROCEDURE: OXIDize 
## PURPOSE: Oxidization routine, invoked once per base addition. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW OXIDize $Col <multiline> 
TRANsfer BlockVent 2 
TRANsfer PressureIodine 2 
TRANsfer IodineToColumn($Col) 12 
TRANsfer BlockFlush 4 
SLEep 20 
TRANsfer ReverseFlush($Col) 8 
TRANsfer ACNToWaste 2 
TRANsfer ACNToColumn($Col) 13 
TRANsfer FlushToColumn($Col) 7 
TRANsfer ACNToColumn($Col) 13 
TRANsfer ReverseFlush($Col) 7 
TRANsfer ACNToColumn($Col) 15 
TRANsfer FlushToColumn($Col) 9 
164 
TRAN sfer BlockFlush 5 
## PROCEDURE: WASH 
## PURPOSE: Clean up delivery lines after a run has been terminated. 
## INPUTS: $Col - Comma-separated list of active columns. 
NEW WASH $Col <multiline> 
SAFe Yes 
TRANsfer ReverseFlush($Col) 15 
TRANsfer BlockFlush 3 
TRANsfer ACNToColumn($Col) 20 
TRANsfer ReverseFlush($Col) 15 
TRANsfer BlockFlush 3 
TRANsfer ACNToColumn($Col) 20 
TRANsfer FlushToColumn($Col) 15 
TRANsfer ACNToWaste 4 
TRANsfer BlockFlush 8 
END 
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